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Polycystic kidney disease (PKD) is a devastating genetic disorder that is 
one of the most common potentially fatal inherited diseases and is the fourth 
leading cause of end-stage renal disease (ESRD) in the US5,6,7. The most 
common form of the disease, autosomal dominant PKD (ADPKD) affects up to 1 
in 500 and costs >$2 billion/year to care for those afflicted. As the name implies, 
PKD is characterized by the presence of large, fluid-filled cysts that expand within 
the kidney, distorting and damaging parenchyma and ultimately resulting in loss 
of kidney function. Currently, there are no FDA-approved treatments for PKD, but 
there is hope that a thorough understanding of disease pathogenesis will 
facilitate the development of treatment strategies that target key drivers of 
disease progression.  
In this dissertation, I will summarize what is known about clinical and 
pathologic features of the disease, focusing on ADPKD and a previously 
underappreciated aspect of disease pathophysiology—the role of inflammation, 
especially involving innate immune cells known as macrophages. This work will 
then describe details of investigations undertaken to better understand the 
genesis of pathologic macrophages in the cystic kidney and their role in disease 
progression. These studies have revealed the regulatory cytokine IL-10 to play a 
key role in this process and thus have identified that cytokine and its signaling 
partners as potential targets for therapeutic intervention in PKD. 
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ADPKD – CLINICAL PRESENTATION 
 ADPKD is a remarkably common genetic disease caused by mutations in 
one of two genes PKD1 (polycystin 1, PC1; ~85% of patients) or PKD2 
(polycystin 2, PC2: ~15% of patients). For comparison, it is ~10x more common 
than Sickle Cell Disease, ~15x more common than Cystic Fibrosis, and ~20x 
more common than Huntingtonʼs Disease 8. In the typical presentation of 
ADPKD, large fluid-filled cysts derived from non-functional tubules are detectable 
around age ~35, continue to expand throughout the lifetime of the patient, 
causing extensive damage to the surrounding normal parenchyma 9-11. Diagnosis 
is usually made by ultrasound in patients with a family history or clinical suspicion 
12. In humans and animal models alike, cysts normally begin formation in utero 
and are detectable by age 30 in up to 70% of human patients 12, 13. Patients 
typically develop hypertension, hematuria, and other features of chronic kidney 
disease (e.g., polyuria, sub-nephrotic proteinuria). An important clinical feature is 
intractable pain, which is unfortunately not uncommon and can be caused by cyst 
enlargement, rupture, blood clots, and nephrolithiasis. As hinted above, the 
majority of affected individuals reach End Stage Renal Disease/Failure 
(ESRD/ESRF) by the 5th to 6th decade of life, but there is marked variation in the 
disease course, including rare patients who present with early onset disease. 
	   2	  
There are many factors that contribute to the severity and rate of progression of 
the disease, and these will be discussed later in this chapter.  
 Since the gene products involved in ADPKD are expressed in other 
tissues, non-renal manifestations are common. Approximately 80% of patients 
have liver cysts.  Aneurysms are common. In fact, ruptured aneurysms in the 
Circle of Willis with accompanying subarachnoid hemorrhage accounts for ~5-
10% of deaths in patients with ADPKD. Cardiovascular complications are 
common. Mitral valve prolapse and other valve abnormalities are seen in ~25% 
of patients. About 40% of patients die from cardiovascular-related complications 
9, 14, 15. 
 
ADPKD-PATHOLOGY 
 Kidneys are typically large and heavy (~2 kg) and architecture is 
dramatically distorted by numerous, variably-sized cysts. The cysts are typically 
unilocular and generally are filled with variable material: clear fluid, hemorrhagic 
fluid, gelatinous material, clotted material, cheesy, grumous material, etc. Cysts 
are most commonly derived from collecting duct, and lining cells are often 
flattened, but may show more cuboidal appearance 10, 16. Micropapillary 
excrescences are also common. In the surrounding parenchyma, there is atrophy 
and fibrosis, with accompanying inflammation, including lymphocytes and 
macrophages. Any non-atrophic nephrons tend to show hypertrophy, with 
glomerular enlargement and enlarged proximal tubules 17. 
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ADPKD-TREATMENT 
 There are no currently FDA-approved specific treatments or therapy for 
PKD, though a recent clinical trial showed some efficacy for a drug that targets 
the vasopressin receptor 18, which will be discussed below. Thus, renal 
replacement therapy, usually with dialysis and then eventually transplantation is 
the most common outcome. A great deal of current research is focused on 
developing new therapies for PKD. This is a significant challenge, since therapies 
would have to be life-long and would be best if begun before a great amount of 
irreparable amount of damage has occurred in the kidney. To accomplish this, a 
thorough understanding of disease pathophysiology would be helpful to identify 
viable targets for therapy. Importantly, since PKD typically progresses very 
slowly, effective therapies, if begun early enough, would require only modest 
effects to be clinically significant. A modest ameliorative effect over decades 
could be sufficient to preserve renal function for the lifetime of the patient. Thus, 
understanding not only the genetics but also the factors that modify disease 
progression could be fruitful. Some of the work to date in this area is discussed 
below. Moreover, a focus of this dissertation is to advance our understanding of 
PKD pathophysiology for this purpose, and that work will be detailed in the 
ensuing chapters. 
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ADPKD-GENETICS AND PATHOPHYSIOLOGY 
PKD1 encodes for PC1, which is a large 11 transmembrane protein associated 
with primary cilia. Mutations in PKD1 account for ~85% of ADPKD patients. 
PKD2 encodes for PC2, a 6 transmembrane domain protein that functions mainly 
as a cation channel. PC2 is related to Transient Receptor Potential Cation 
(TRPC) calcium channels and, importantly, interacts with the C terminal domain 
of PC1. PC2 is also associated with primary cilia; mutations in the encording 
gene account for ~15% of ADPKD patients. Finally, and perhaps most 
interestingly, ~10% of cases present with no family history of PKD, i.e., there is 
most likely de novo mutation. Mutations in either of the polycystins result in 
essentially identical ADPKD disease manifestations, although patients with PC2 
mutations tend to have increased renal survival and fewer overall complications, 
due to slightly milder disease manifestations and a later onset of disease 5, 19. 
 Rodent models have provided important information regarding disease 
pathogenesis 20, 21 22 23. Mutations in PC1 typically present as loss of function and 
include truncation, as well as missense mutations. Location at the primary cilia 
appears to be key, as mutations in PC1 and PC2 appear to disrupt ciliary 
function. Mutations in other ciliary genes also cause clinically distinct cystic 
diseases, some slightly more severe and all clearly distinguishable from ADPKD, 
e.g., ARPKD 24 and nephronophthisis 25, 26. Thus, many investigators refer to 
cystic diseases collectively as “ciliopathies.” 
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 The primary cilium is believed to be important in mechanosensation. In the 
tubule, this may be manifested as flow sensation. How this ciliary function relates 
to cyst formation, however, is incompletely understood. Nevertheless, abnormal 
cystic tubular epithelial cell proliferation appears to be an essential element of the 
resulting phenotype 19, 27. A number of signaling pathways have been implicated 
in driving proliferation 27, though cAMP formation appears to be a particularly 
important event 9, 28-30. Normal kidney epithelial cells regulate the response to 
cAMP using Ca2+ signaling, leading to a growth inhibition. With the loss of 
polycystin-driven Ca2+ regulation, ADPKD cyst cells respond in an aberrant 
fashion to cAMP, actively proliferating. In the collecting duct, the kidney segment 
from which most cysts originate, cAMP formation is primarily driven by 
vasopressin. This is the underlying rationale for PKD therapies that use 
tolvaptan, an antagonist of the V2 vasopressin receptor that is expressed in the 
collecting duct. Indeed, clinical trials using this drug showed slower kidney 
expansion in treated patients 18. However, the treatment was not approved by the 
FDA due to concerns over toxicity. 
 
ADPKD-MODIFIERS OF DISEASE 
 As mentioned above, the disease course for ADPKD is highly variable and 
can be influenced by many factors. Genetics of PKD can alter disease severity 
and age of presentation 15, 29, 31, especially the penetrance of the mutation and 
whether it is a truncating mutation. There are many mutations; to date, 
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approximately 314 different loss-of- function mutations in the PKD1 gene have 
been identified in 400 families, 91 truncating mutations in PKD2 from 166 families 
have been described, as well as additional missense mutations; making up about 
one fourth of the cystin mutations, and none of them are the same. Some 
mutations, such as homozygous hypomorphs, have been shown to be more 
severe clinically than others, like heterozygous hypomorphs 31, 32. The severity of 
disease has been recently shown to correlate with the position of the mutation, 
and the subsequent disruption in signaling that occurs due to the mutational 
location. Dosage levels attributable to PKD genetic and allelic variability, as well 
as other possible gene modifier and environmental effects, likely underlie the 
large phenotypic variability among affected individuals. Either overexpression or 
lowering of Pkd1 protein levels in murine models is sufficient to cause cystic 
disease, suggesting that dysregulation of polycystins, rather than complete loss 
of function, is what leads to PKD. It seems likely, though it is not yet known, that 
the level to which certain pathways are upregulated in cysts could affect the rate 
at which they progress.  
Injury can accelerate the progression of PKD both in humans and in 
animal models 23. Using an inducible Pkd1 knockout adult mouse model, it was 
recently discovered that renal injury resulting from ischemia/reperfusion (IR) 
accelerated PKD progression 33. Another group showed that injury induced by 
the nephrotoxicant 1,2-dichlorovinyl- cysteine (DCVC) after Pkd1-gene 
inactivation accelerated adult cyst formation 34. Furthermore, multiple groups 
have shown that Pkd1 or Pkd2 haplo-insufficiency alone was sufficient for 
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microcyst formation and increases in tubule dilation, only after acute injury 35, 36. 
In many of these mice examples, the repair response to the injury was studied 
and thought to play a role in the development of PKD, though this will be 
discussed later. 
 
THE INNATE IMMUNE SYSTEM AS A MODIFIER OF PKD 
 The role of inflammation and the immune system in PKD has become 
apparent in recent years. As mentioned previously, expanding cysts cause 
damage to the surrounding healthy tubules. This continuous damage brings in 
immune infiltrates, especially including innate immune cells known as 
macrophages. We and another lab have found that the abundant macrophages 
are present within the cystic kidneys in PKD 4, 37. In these studies, some of which 
will be detailed in Chapter 2, macrophages were identified and quantified in both 
human PKD (ARPKD and ADPKD), as well as mouse models of disease. 
Importantly, using a non-orthologous model of PKD, cpk mice, which possess a 
recessive mutation in the cilia-associated Cys1, depletion of macrophages was 
shown to slow cystic epithelial cell proliferation and cyst growth and preserve 
renal function 4 (Fig 1.1 and 1.2). Similar results were observed in an 
orthologous mouse model of ADPKD 37, suggesting that macrophages play a role 
in PKD pathogenesis regardless of the underlying genetic origin of the disease. 
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Figure 1.1: Clodronate liposome treatment of cpk/cpk mice reduces macrophage 
load, renal cortical cyst area, and renal cortical cell proliferation. (A) Formalin-fixed, 
paraffin-embedded kidney tissues from PN10 cpk/cpk mice treated with either vehicle 
(left) or clodronate liposomes (right) were sectioned and stained with hematoxylin and 
eosin. Each image is a representative field from one mouse of four examined per 
condition. Scale bars represent 100 μm. (B) Average cortical cystic index (cortical cyst 
area/total cortical area) was calculated from measurements of kidneys from animals 
treated with vehicle or clodronate liposomes, two per condition. (C) Formalin-fixed, 
paraffin-embedded kidney tissues from PN10 cpk/cpk mice treated with vehicle (left) or 
clodronate (right) were sectioned and stained by immunohistochemistry using a 
monoclonal antibody against F4/80. A representative image from one of two different 
mice for each condition is shown. Scale bars represent 25 μm. (D) The mean area (μm2) 
of F4/80 staining per high-powered field (HPF) in sections of kidney cortex described 
in C was measured from 2 kidneys each of mice treated with either vehicle or clodronate 
liposomes. (E) Formalin-fixed, paraffin-embedded kidney tissues from 
PN10 cpk/cpk mice treated with vehicle (left) or clodronate (right) or were stained with 
an antibody to Ki-67. A representative image from one of two mice per condition is 
shown. Scale bars represent 25 μm. (F) Ki-67+ cells/mm2tissue in PN10 cpk/cpk mice 
treated with either vehicle or clodronate. 
Taken from: Swenson-Fields4 et al. 
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Figure 1.2: Clodronate treatment of cpk/cpk mice improves kidney function. 
Serum BUN concentration was measured in PN10 mice of the indicated 
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MACROPHAGES 
 Macrophages are complex components of the innate immune system that 
are known to play a role in both immune protection and a variety of disease 
states. To better understand the role of macrophages in the kidney and 
particularly in PKD, it is useful to understand their origin and biological 
characteristics, as well as their known functions in processes like tumor biology 
and tissue repair. Macrophages arise from mononuclear precursor cells, which 
develop in the bone marrow in the adult. Macrophages were originally discovered 
in the early 1900s, initially described as phagocytic cells that helped to eliminate 
pathogens from the host 38, 39. Over the years it has become clear that their 
phagocytic functions are extensive and broad, including not only pathogens but 
also cellular debris and other foreign material. 
 Macrophage Polarization. Macrophages, however, are not simply 
unregulated eating machines. This began to become clear in the early 1980ʼs, 
when it was discovered that macrophages could functionally alter their phenotype 
in order to respond to different stimuli 38-41. That is, macrophages were found to 
take on different roles and abilities in response to cues from their surrounding 
microenvironment. This differentiation phenomenon (“polarization”) and the role it 
plays in progression of PKD is the primary focus of this dissertation. 
 Macrophage polarization results in the generation of two main types of 
macrophages that were originally described: M1 and M2 1, 40, 42-44. This naming 
was based on the major T helper cell subtypes, Th1 and Th2, because cytokines 
	   11	  
produced by Th1 and Th2 cells were found to promote M1 and M2 polarization, 
respectively (discussed in more detail below). Unlike their T cell counterparts, 
however, M1 and M2 phenotypes are not static, end-point states. Rather, 
macrophages show remarkable plasticity and can change quite rapidly, 
depending on the presence of activating stimuli in the immediate 
microenvironment 2, 44, 45. This plasticity allows them to switch phenotypes into 
diverse functional states, including the artificially divided M1 or M2 state. There 
can even be a spectrum of macrophages that express mixed M2 or M1/M2 
profiles in vivo, some of which can be poorly recapitulated in vitro. Macrophage 
plasticity is quite relevant to tissue homeostasis and disease, as is discussed 
below 42 and shown in Figure 1.3. The M1-M2 switch is particular relevant in 
kidney disease and will be demonstrated in the context of PKD in Chapter 2 of 
this document. Regulation of this switch is complex, but one pathway know to be 
important involves AMP Activated Protein Kinase (AMPK). Activation of this 
kinase enhances mitochondrial biogenesis, which increases the generation of M2 
macrophages, which are characterized by oxidative metabolism and limited 
glycolysis 46. 
 M1 macrophages. M1 macrophages were first described in 1983 and 
called “classically activated 38, 39. It was shown that Th1 type cytokines like IFNγ 
can drive their appearance. M1 macrophages are sometimes called 
“inflammatory” in part because they are characterized by the production of 
inflammatory mediators such as TNFα, iNOS, IL-6, and TGFβ. In the mouse, M1 
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macrophages are recognized by expression of markers: F4/80+; Cd11c−; MR−; 
Ly6Chi. Inflammatory stimuli like LPS, TNFα, or in some cases GM-CSF can drive 
their differentiation 38, 42, 43, 47. M1 macrophages play an important role in the 
response to host infection from bacteria, parasites, or other foreign attackers 42. 
M1 macrophages are also critical for host response to acute injury, especially by 
the release of effector molecules (reactive oxygen and nitrogen intermediates) 
and inflammatory cytokines (IL-1β, TNF, IL-6) that participate as inducer and 
effector cells in polarized Th1 responses 42. M1 macrophages are capable of 
activating the adaptive immune system and mediate resistance against 
intracellular parasites and tumors 3, 43.  
 M2 macrophages. With the identification of M1 macrophages, it was 
found that macrophages could also respond to Th2 cytokines IL-4 and IL-13. 
These were termed “alternatively activated” or M2 macrophages and were shown 
to express markers such as Arg1, Mrc1/CD206, Fizz1, Ym1, and IL10). 
Alternatively activated macrophages generally show high expression of Arg1, 
mannose receptor (MRC1), and variable IL-10. M2 macrophages are detected in 
mice as F4/80+; Cd11c−; MR+; Ly6Clo. M2 macrophages have immunoregulatory 
capabilities and are critical regulators of tissue remodeling. They also are known 
to influence tumor progression. M2 macrophages can arise from signals such as 
apoptosis and can protect the host from excessive inflammation and initiate 
healing. M2s secrete anti-inflammatory mediators, promote tissue repair, and 
regulate immune response to infection 38, 39, 42. Importantly, M2 macrophages 
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have been found to promote growth in many disease and injury models, due in 
part to the effect that IL-10 has on the surrounding immune and non-immune 
cells 48-50. For example, M2 macrophages can be programmed by mesenchymal 
stem cells, increasing their IL-10 expression. The resulting M2s suppress the 
inflammatory response and promote proliferative repair phase of nearby epithelial 
cells 51. This pro-proliferative capacity of M2 macrophages, driven in part by IL-
10, is highly relevant to kidney disease, and this dissertation provides evidence 
that it is particularly relevant in PKD.  
 Because M2 macrophages were found to have such diverse functional 
roles (and markers), they have further been characterized into subcategories 
based on nuanced responsibilities, though some key characteristics remain the 
same. There are three general M2 subtypes (Figure 1.3 (C)) that are generally 
recognized in current literature: 2a, 2b, and 2c, categories that are largely based 
on their gene expression profiles 39, 52. M2a are pro-fibrotic, often termed wound-
healing, and are activated by a combination of IL-4 and IL-13. M2a macrophages 
also interact with the Th2 response to parasitic infections, and are the prototypic 
pro-fibrotic M2 subtype. M2b are induced via stimuli such as immune complexes, 
LPS, IL-1R ligands, and Toll-like receptor activation. M2b macrophages are the 
immune-regulating cells, secreting IL-10 among other cytokines to rein in the 
inflammatory response caused by M1 macrophages. M2c are regulatory and 
exhibit strong anti-inflammatory capabilities, and are most often involved in tissue 
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repair and remodeling. They are induced via a variety of factors, including IL-10, 
TGFβ, and glucocorticoids 1, 42, 52-54. 
 While this sub-classification is widely used and has some utility, some 
investigators feel that the rigid categorization does not capture the diversity of 
phenotypes that can exist, especially since macrophages are sometimes found 
that do not clearly fall into one single category 55. In 2008 the idea that 
macrophages could exist along a spectrum of activation (Figure 1.3 (B)) was 
proposed, an idea particularly relevant to M2-like macrophages 38. This idea is 
consistent with one of the defining characteristics of macrophages mentioned 
above, i.e., their plasticity. Macrophages are highly plastic and responsive to 
environmental stimuli in vivo, making a rigid classification scheme difficult to 
provide real-world utility 55. It is perhaps more useful to think of macrophage 
polarization states as a continuum regulated by external signals and a continuity 
of expression of numerous effector genes. This paradigm extends not only to M2 
subtypes but also the M1/M2 dichotomy, as mentioned above. 
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Figure 1.3: The M1/M2 paradigm and the sub-classifications of M2 macrophages. (A) The 
M1/M2 macrophage model indicates that M1 macrophages are activated by the presence of LPS 
or interferon in the microenvironment while M2 macrophages arise due to various other factors, 
most commonly IL-4 or IL-13. (B) Macrophages more accurately exist along a spectrum, 
depending on the cues found in their microenvironment. These highly plastic cells can have 
varying degrees of a fight or fix reaction, and can easily convert to adapt to the threat to the host. 
(C) Three subsets of M2 macrophages are commonly described, listed are the primary activators 
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MACROPHAGE POLARIZATION IN DISEASE 
 A full characterization of specific macrophage polarization states existing 
in vivo, including in any particular disease state, has not been achieved due to 
difficulties resulting from macrophage plasticity and the rate at which they change 
phenotypes when placed into a new environment 38, 42, 56, 57. Nonetheless, “M1-
like” macrophages found in in vivo settings, including the kidneys that share 
similar markers with the classically defined M1 macrophages have been shown 
to play an important role in the inflammatory response during chronic or acute 
injury. In turn, “M2-like” macrophages have been shown promote the tissue repair 
and regeneration of cells post-injury 58-60. Loss of an M1 or M2 phenotype occurs 
in vivo in dividing macrophages isolated from bone marrow, while non-dividing 
macrophages from the spleen kept an M2 phenotype; this indicates that 
macrophages plasticity in vivo is based on programming factors in the 
microenvironment 56, 57, 61. In this section, specific examples of macrophage 
polarization in disease will be discussed, ending with an emphasis on kidney 
disease. 
 Tumor Biology. Both M1-like and M2-like can promote tumor 
progression, depending on the stage of the tumor and the type of cancer 38, 62-64. 
There is correlation between a high number of tumor-associated macrophages 
(TAMs) and poor prognosis in thyroid, lung and liver cancers 65. TAMs very 
generally express Arg1 (mouse models only), Ym1, Fizz1 and Mrc1, however in 
each cancer there are distinct phenotypes of TAMs; with M1 and M2 as the 
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extremes to compare them to. This model, where there is no clearly defined or 
understood macrophage phenotype, is really where the continuum idea arose 
from. It seems that M1s, expressing NFκB, play a role in the initiation and 
promotion of tumors, while M2 cells play a role in the invasion and migration of 
tumor cells, as well as in assisting in hypoxic survival 38. Extensive and long 
inflammation has been considered as a possible 7th marker of cancer, indicating 
the importance that macrophages are thought to have in tumor progression. 
However, a clear role for a specific phenotype has not yet been discovered, most 
likely because of the complexities of studying macrophages in vivo rather than in 
vitro, as well as the fact that mouse and human macrophages do not necessarily 
have overlapping prominent markers 62 38. M2 macrophages are associated with 
increased tumor growth, invasiveness and metastasis in Renal Cell Carcinoma; 
this is due to secretion of pro-angiogenic factors, induced cells migration, and 
modulation of the tumor response. The expression of CD163 and M-CSF was 
found to correlate with a worse prognosis in the setting of type 2 Papillary RCC 63, 
65. An increased infiltration of tumors by M2 macrophages decreases the 
chances of survival, mostly due to increased distant metastasis in both breast 
and pancreatic cancer 63, 65. 
 Cardiovascular Disease and Obesity. Macrophages are important in the 
pathophysiology of atherosclerosis. It is believed that in vessels macrophages 
take up cholesterol and become plaques. In particular, M1 macrophages are 
elevated in patients who experience a cardiac event related to atherosclerotic 
	   18	  
disease. A specific contribution for M2 cells in atherosclerosis is still debated 38. 
A recent study in mouse models of atherosclerosis has revealed that the balance 
of M1 and M2 macrophages in plaques can indicate disease progression (M1 
majority) or regression (M2 majority) 66. The relevance in human patients has yet 
to be studied, and the mechanism by which an M2 subtype may prevent disease 
progression has yet to be determined 66. However, in patients with chronic kidney 
disease (CKD), the incidence of cardiovascular events was higher in those with 
high serum levels of the M2 cytokine IL-10. Macrophages may also play a role in 
hypertension, another vascular disease that increases risk of atherosclerosis. 
Depletion of macrophages and neutrophils eliminated the hypertensive response 
to Angiotensin II in mice, indicating a potential role for immunosuppression in 
hypertension treatment 67. 
 Macrophages can influence metabolic disease as well. The observed 
macrophages in obese mice are M1-like, while lean animals had macrophages 
that were skewed towards an M2 profile. In preliminary studies, the frequency of 
diabetes mellitus was also higher in IL-10 high patients, though further studies 
need to be done 68. Obesity decreases IL-10 expression and synthesis, resulting 
in chronic kidney inflammation, but spleen-derived IL-10 can protect against 
obesity-induced inflammation due to altered macrophage function rather than a 
change in macrophages recruitment 69, 70. IL-10 also has been show to attenuate 
glomerular fibrosis in high fat diet male mice, with improved blood pressure and 
decreased inflammation, while injury is worse yet salvageable in IL10KO mice 69. 
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 Kidney Disease. Macrophages are key regulators and effectors in kidney 
disease, including both tubulointerstitial and glomerular disease. Macrophages 
come to reside in the kidney very early during development 71. They are present 
in the kidneys before nephrons, suggesting that they may have a role in the 
prenatal stages of kidney development. Despite their early presence in the 
kidney, these so-called “resident” renal macrophages are also thought to be of 
bone marrow origin 71.  Kidney mononuclear cells have 5 subtypes based on 
surface marker expression and arise both from the yolk sac and the bone 
marrow, termed resident and migrating respectively 60. However, no matter the 
surface markers, all of these macrophages react fairly similarly to cytokines. 
Renal epithelial cells have the ability to change macrophage phenotype from M1 
to M2 72, 73. In the kidney the primary role of macrophages is ongoing immune 
surveillance, maintaining homeostasis and modulating physiological function 71, 
74, 75. Dysregulation of this role can be detrimental to the kidney in times of injury 
or disease, as will be discussed below.  
 Macrophages in Acute Kidney Injury. Macrophages undergo a 
phenotypic shift from M1 to M2 to help with repair after ischemia/reperfusion (IR), 
a common model for acute kidney injury (AKI). The precise cue that drives this 
switch is unknown, but tubular epithelial cells can induce alternative activation of 
BMDMs, even in the absence of IL4Rα or STAT6 72. Recovery takes much longer 
if the M1-M2 switch does not happen 76. In IR, monocytes are recruited 24 hours 
after reperfusion, mature into macrophages, increase in number through day 7 
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after injury. In the first day or so the macrophage infiltrate is predominantly 
inflammatory (M1). The infiltrate helps to destroy and clear injured tissue. Thus, 
depletion of macrophages at the time of injury was shown to be protective 77. 
Subsequently, the macrophages transition from pro-inflammatory state, which 
promotes tubular injury, to a reparative phenotype after 48-72 hours. In contrast, 
macrophage depletion during the repair phase worsens injury and delays tubule 
proliferation. Immediate adoptive transfer of M1 macrophages promoted injury, 
while injection of M1 macrophages 3 days after injury led to an induction in 
repair. When isolated from the injured kidney and sorted for additional study, 
however, it was discovered that the M1 cells had switched to a more M2-like 
phenotype 77, 78. 
 Further evidence of M2 macrophage involvement in AKI can be found by 
examining the appearance and function of the M2 cytokine IL-10. There is an 
increase in IL-10 production for 7 days after IR injury and this peaks at day 3, 
which is when IL10KO mice had greater tubular injury than WT as well as 
increased serum creatinine levels 79. IL10KO mice also had an increased number 
of infiltrating macrophages that expressed high levels of IL-6 and TNFα, as well 
as less Ki67 staining, all reaching statistical significance on day 3 post injury 79, 
80. IL-10 injection pre- or immediately post-injury can protect from AKI, perhaps 
by upregulating netrin 48, 79, 81. Moreover, IL10 overexpressing macrophages 
introduced at the time of acute injury not only reduced pro-inflammatory 
cytokines, but preserved renal function and limited tubular injury 82, 83. In a 
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different model of AKI involving sepsis in the rabbit, kidney injury is reduced with 
hydrogen sulfide treatment, which promotes M2 polarization via unknown 
mechanisms. With this treatment there is increased IL-10 production, while NFκB 
and TNFα levels are reduced 51, 84. Collectively, these studies indicate that IL-10 
suppresses inflammation in acute kidney injury. 
 These studies highlight the idea that transition from M1 to M2 
macrophages is critical and maximizes functional and structural recovery 
following injury 56. As further evidence of this point, infusion of IL-4 treated 
macrophages promoted renal tubular cell proliferation after IRI, while infusion of 
IFNγ treated macrophages worsened disease 56, 72. M1 or unprogrammed 
macrophages worsened injury in AKI mouse model 51. Socs3 KO mice had better 
renal function due to an increased tubular cell proliferation and limited initial 
damage. This was found to be due to a phenotypic switch from M1 to M2 leading 
to higher numbers of alternatively activated macrophages with elevated levels of 
IL-6 and IL-10. The result was better preservation of renal function 80. While the 
M1-M2 phenotypic switch is essential for effective repair, persistent inflammation 
promotes tubular atrophy and fibrosis in AKI models, which is also driven by M2-
like macrophages 71, 85. Thus, M2-like macrophages can be either adaptive or 
pathologic, depending on the physiologic context. 
 Macrophages in Acute Glomerular Disease. In addition to AKI and 
CKD, macrophages also are key modifiers of glomerular disease. Macrophages 
are a major cellular component within glomeruli in many acute glomerular 
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diseases. For example, their presence correlates with a worsened outcome in 
lupus nephritis 86, 87. Persistent pro-inflammatory macrophage presence also 
plays a role in forms of crescentic glomerulonephritis (GN). Ablation of 
macrophages has shown to improve the prognosis of crescentic GN resulting 
from lupus or other causes 88, 89.  Many studies have found that prolonged M1-
like macrophages presence can exacerbate glomerular injury, while prolonged 
M2-like presence can lead to tubulointerstitial fibrosis and impaired renal function 
46, 51, 75, 90. Thus, in glomerular disease, as with tubulointerstitial disease, 
macrophages can have both adaptive and pathologic functions. 
 Macrophages in Chronic Kidney Disease. Chronic kidney disease 
(CKD) refers to disease that results from recurrent or progressive injury to 
components of the kidney, including glomeruli, tubulointerstitium, and vessels. 
There are many relevant models for CKD, including unilateral ureteral obstruction 
(UUO). In UUO obstruction is a significant component and ultimately results in 
CKD. Persistent presence of macrophages drives renal scarring and chronic 
fibrosis in UUO, which can result in organ failure. As with IRI, in UUO M1 (Ly6Chi) 
macrophages are originally recruited to the injured kidney, and M2-like (Ly6Clo), 
pro-fibrotic macrophages then develop from these 71, 91. Systemic depletion of 
macrophages by administration of the bisphosphonate clodronate attenuated 
fibrosis in UUO 75, 90, 92. This ameliorative effect is believed to be related to the 
loss of functional M2-like macrophages. 
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 Macrophages in Polycystic Kidney Disease. As discussed above, the 
kidneys in PKD are infiltrated by macrophages, and we and others have shown 
that their presence can promote disease progression 4, 37. In this dissertation, I 
will describe experiments that determine markers that define these pathogenic 
macrophages, as well as fully characterize their interactions with cystic epithelial 
cells (Chapter 2). Similar to other disease states described here, these 
macrophages take on an M2-like phenotype in PKD kidneys. I show that the 
polarization is driven by interaction with cystic epithelial cells, and these polarized 
macrophages display enhanced ability to promote cyst cell proliferation. As 
detailed above, interactions between epithelial cells and macrophages can be 
advantageous, by promoting repair after injury. However, these data suggest a 
model wherein reciprocal interactions between cystic epithelial cells and 
macrophages are pathogenic in PKD, since cyst cells are already 
hyperproliferative. 
 In Chapter 3, I explore signals responsible for pathogenic polarization, 
focusing on the role of IL-10. This cytokine has been implicated in repair in other 
settings. In the context of PKD, I provide evidence that its secretion is required 
for polarization. The IL-10 subsequently acts in an autocrine manner to promote 
differentiation to a macrophage phenotype that has enhanced pro-proliferative 
capabilities. In Chapter 4, I look at components of signaling pathways 
downstream of IL-10. In particular activation of Stat3 is shown to be required for 
acquisition of the pathogenic phenotype. Also, using gene expression data, I 
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describe likely pathways that set the IL-10-dependent differentiation process in 
motion. Collectively, these data imply that IL-10 and its signaling partners may be 
potential targets for therapy in PKD. 
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Chapter Two 
 




 Macrophages constitute an important part of the immune response to 
injury. In the kidney, macrophages are essential effectors of both repair and 
fibrosis following injury 58, 93. Soon after acute kidney injury, monocytes are 
recruited to the kidney, where they differentiate into macrophages. As discussed 
in Chapter 1, these macrophages most commonly have an “inflammatory” or M1 
phenotype, expressing factors such as IL-1, IL-6, TNF, iNOS 94, 95. M2 
macrophages appear subsequently as a result of either conversion of M1 due to 
stimulation by local environmental cues or the recruitment of new monocytes 95. 
Persistence of the M2 and M2-like macrophages, which can result from 
sustained, ongoing injury, can promote fibrosis and scarring 95. 
 PKD is a genetic kidney disorder in which injury plays a prominent role. 
PKD results in the formation and slow expansion of numerous fluid-filled cysts 
within the kidney. These cysts dramatically distort the renal parenchyma and 
result in fibrosis and renal failure in most patients. The expansion of each cyst 
results in local injury by compressing surrounding tubules, vessels, and 
lymphatics. It is hypothesized that this persistent injury, in fact, is largely 
responsible for the scarring, fibrosis, and ultimate failure of the kidney in PKD 96. 
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 Since both acute and chronic kidney injury play an important role in PKD 
pathophysiology, it stands to reason that the immune system, especially 
macrophages, would be an important component of the disease. In fact, several 
groups have documented the presence of macrophages in PKD kidneys 36, 97. 
However, the specific phenotype of the macrophages was not investigated. This 
chapter examines both mouse models of PKD and human tissue to define 
macrophage phenotypes. This analysis reveals that a majority of macrophages 
existing in PKD kidneys of both study mice and human patients express M2 
markers. Moreover, macrophage differentiation is influenced by either direct 
contact with primary ADPKD cells or exposure to ADPKD cell secretions in 
conditioned media. Signals from ADPKD cells not only influence naïve cells but 
are also sufficient to switch the expression profiles of previously polarized 
macrophages. Thus, the macrophage phenotype that is predominant in PKD is 
not only novel and distinct but arises due to factors produced by cystic epithelia. 
 
2. Methods 
 Media: ADPKD media is DMEM/F-12 supplemented with 5% FBS, 15 mM 
HEPES, 5 μg/ml insulin, 5 μg/ml transferrin, and 5 ng/ml sodium selenite (ITS, 
BD Biosciences) plus penicillin (100  U/ml), streptomycin (130  μg/ml) 
(Pen/Strep). THP-1 media is RPMI-1640 media containing 10% FBS, 2 μM L-
glutamine and Pen/Strep. RAW media is DMEM with the addition of 10% FBS, 
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P/S, and 2 mM L-glutamine. XVIVO-10 (Bio Whittaker, Walkersville, MD) 
contains L-glutamine, gentamicin, phenol red, P/S, and 10 mM HEPES buffer.  
 Cells: THP-1 (#TIB-202) cells were obtained from ATCC (ATCC.org). The 
cells were passaged as suspension cells in THP-1 media until needed for assay. 
THP-1 cells were differentiated at a final density of 2.0 x 106 cells in 6-well dishes 
with the addition of 200 nM PMA (phorbol myristate acetate) to the media for 3 
days, making them adherent. THP-1 cells were switched back into non-PMA 
media for 3 to 4 days after differentiation before being programmed for 
proliferation assays or protein analysis. Programming took place with the addition 
of ADPKD conditioned media (CM) made in XVIVO-10, XVIVO-10, and combined 
with various inhibitors, as indicated in the figures. 
 RAW 264.7 cells (TIB-71) were obtained from ATCC (ATCC.org) and were 
carried and used for up to 20 passages. Cells were seeded at a final density of 
2.0 x 106 in 6-well plates for all protein and RNA analysis. Cells used for 
proliferation assays were seeded at a final density of 1.0 x 106 in 6-well plates in 
RAW media. Programming took place with the addition of ADPKD CM made in 
XVIVO-10 or RAW media, the appropriate controls, and any necessary inhibitors 
or cytokines, as indicated in the figures. 
 Primary cyst epithelial cells obtained from the cavities of cysts on the 
surfaces of ADPKD kidneys (ADPKD cells). Both these and non-cystic kidneys 
(NHK cells), which were derived from cortical tubule fragments of non-cystic 
kidneys, were supplied by the PKD Biomaterials Research Core laboratory at 
	   28	  
KUMC and cultured up to 2 passages or 7 days, whichever occurred first. These 
cells were used to produce PKD CM, as well as in direct and transwell 
proliferation assays. 
 PCR: Total RNA was isolated from cells (macrophages or macrophages 
plus renal tubule cells) harvested after 18 h culture using RNeasy Miniprep kit 
(Qiagen) according to the manufacturerʼs instructions. 1.5 μg RNA was used as 
template for cDNA synthesis using High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems; Foster City, CA) in a 20 μl reaction. For semi-quantitative 
RT-PCR 1-2 µL of the cDNA reaction was used in a 20 μl PCR mixture. Phusion 
High-Fidelity DNA polymerase was used and PCR carried out using the 
manufacturerʼs protocol (New England Biolabs; Ipswich, MA). The housekeeping 
gene Gapdh was used as the endogenous control. Cycle conditions and primers. 
PCR products after amplification were analyzed by 2% agarose gel 
electrophoresis in 1X TAE buffer. Real-time quantitative RT-PCR (qRT-PCR) was 
performed on Mx3005P using Sybr Green Master Mix (Agilent). The thermal 
cycler conditions were 95 °C for 10 m X 1, then 40 cycles of 95 °C for 30 s, 55 °C 
for 1 m, and 72 °C for 1 m, and completed with 1 cycle of 95 °C 1 m, 55 °C for 30 
s, and 95 °C for 30 s. Expression of mouse gene products was normalized to 
mouse Gapdh. The following primers were used:  
Arg1, 5ʼ-CTCCAAGCCAAAGTCCTTAGAG-3ʼ and  
5ʼ- GGAGCTGTCATTAGGGACATC-3ʼ;  
iNos (Nos2), 5ʼ-GTTCTCAGCCCAACAATACAAGA-3ʼ and  
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5ʼ–GTGGACGGGTCGATGTCAC-3ʼ; Mrc1, 5'-CTCTGTTCAGCTATTGGACGC-3' 
and 5'-CGGAATTTCTGGGATTCAGCTTC-3';  
Il6, 5'-CTGCAAGAGACTTCCATCCAG-3' and  
5'-AGTGGTATAGACAGGTCTGTTGG-3';  
Il10, 5'-GCAGCTCTAGGAGCATGTGG-3' and  
5'-ACAGCCGGGAAGACAATAACT-3' and  




M2-like macrophages are present in ADPKD (Autosomal Dominant) and 
ARPKD (Autosomal Recessive) cystic kidneys.  
 To identify macrophages within human PKD kidneys, 
immunohistochemical staining was performed using the macrophage antibody 
HAM56 98, 99. Macrophages were scattered throughout the parenchyma in both 
ADPKD and ARPKD kidneys, including areas adjacent to cysts. Occasionally, 
macrophages were found infiltrating cysts. To determine whether the 
macrophages were M2-like, serial sections were stained with an antibody to 
CD163, a human M2 macrophage marker 100, 101. The staining pattern was similar 
to that observed for HAM56 (Figure 2.1 (A)). The total number of CD163+ cells 
in each field was similar to the number of HAM56+ cells in the same field of the 
adjacent serial section (Figure 2.1 (A)), suggesting that most HAM56+ 
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macrophages were also CD163+. These data confirm the presence of 
macrophages within both ADPKD and ARPKD kidneys and indicate that most 
exhibit an M2-like phenotype. Sections from non-cystic human kidneys (NHK) 
were also stained with HAM56 and anti-CD163 (Figure 2.1 (B)). While far fewer 
macrophages were present relative to PKD, the ratio of CD163+/HAM56+ cells 
was similar. 
 A similar analysis was performed on cpk mice, a non-orthologous, rapidly-
progressing PKD model that phenotypically most closely resembles ARPKD. 
Flow cytometry was employed on cells isolated from cystic kidneys using F4/80 
(murine monocyte/macrophage marker), Cd11c (dendritic cell marker), and Ly6C 
102, 103. Ly6C can distinguish M1-like (Ly6Chigh) from M2-like (Ly6Clow) 
macrophages 59, 104, 105 in F4/80+Cd11c- cell populations. Renal macrophages 
(F4/80+Cd11c-) were elevated in cystic cpk/cpk kidneys compared to wild-type 
(WT) (20% versus 6% of total single cells; Figure 2.2)). Of these macrophages, 
most (66%) were M2-like (F4/80+Cd11c- Ly6Clow). These data show that, as with 
human PKD, cpk/cpk kidneys contain elevated levels of macrophages, most of 
which are M2-like. 
  




Figure 2.1: Macrophages are present in greater numbers in cystic kidneys, and 
are primarily of the M2 phenotype. Formalin-fixed, paraffin-embedded tissues from 
ADPKD (kidney K239) (A) as well as non-cystic kidney (B) were serially sectioned and 
consecutive sections stained by hematoxylin and eosin (left) or by 
immunohistochemistry using the macrophage antibody HAM56 (middle) or an antibody 
to CD163 (right). Scale bars represent 25 μm. Cystic space is indicated by *. The 
arrows indicate macrophage infiltration of cystic epithelium. 




A. cpk sample 
B. cpk macrophages 
Figure 2.2: Cystic cpk/cpk kidneys contain elevated numbers of 
macrophages that are mostly M2-like. (A). Sections from cpk/cpk mice were cut 
and stained for the presence of macrophages using the mouse macrophage marker 
F4/80. (B). Quantitative flow cytometry analysis of single, live cells isolated from 
WT (gray bars) and cpk/cpk (black bars) kidneys. Shown are the percentages of 
single cells that are macrophages (F4/80+CD11c-) (left), M1-like macrophages 
(F4/80+CD11c- Ly6C-hi) (middle), and M2-like macrophages (F4/80+CD11cLy6C-lo) 
(right). Data are presented as mean ± SEM. Kidneys from a total of 9 cpk/cpk and 
8 WT mice were analyzed. ** denotes P<0.01. 
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Characterization of the M2-like PKD macrophage phenotype.  
 To further characterize the macrophage phenotype, primary ADPKD or 
NHK cells were co-cultured with a mouse macrophage-like cell line, RAW264.7 
(RAW cells). This technique allowed us to design PCR primers that were mouse 
or human specific, so that the change in either cell type could be determined. 
These co-cultured cells were then checked for both M1 and M2 related markers, 
and the induction of each marker was compared in NHK vs ADPKD co-culture 
using end-point RT-PCR. In RAW cells co-cultured with ADPKD or NHK cells, 
there was a robust induction of the classic M2 gene Arg1, as well as M2 markers 
CCL13 and 22 in THP-1 and ADPKD co-cultures. However, there was no 
stimulatory effect on Mrc1, which is also a prototypical M2 marker, while 
treatment with IL-4/IL-13 induced both Arg1 and Mrc1, as expected. There was 
no change or a reduction of expression in M1 related genes such as iNos and IL-
6 (Figure 2.3 (A, C, D) and Table 2.1), but these genes were induced by the M1 
polarizing stimulus IFN-γ (Figure 2.3 (A)). We also measured expression of M2-
like cytokine Il10. As with Arg1, Il10 was upregulated in RAW cells following co-
culture with either ADPKD or NHK cells, which was greater in ADPKD cell co-
cultures (11-fold versus 6-fold in NHK co-cultures; Figure 2.3 (B)). These results 
indicate that both ADPKD and NHK cells can induce a macrophage phenotype 
that is M2-like but distinct from the classic, canonical M2 phenotype stimulated 
by IL-4/IL-13. As mentioned in Chapter 1, macrophages have been observed to 
exist as a spectrum rather than being strictly defined as M1 or M2.  
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Figure 2.3: Co-culture with ADPKD cells induces an M2-like expression in MΦ. 
(A) RAW and kidney epithelial cells were cultured together for 2 days and end-point 
PCR was run to look at polarization markers. Co-cultured macrophages had a 
distinctly different expression profile when compared to cells exposed to IFNγ (M1) or 
IL-4/IL/13 (M2). (B) RAW macrophages were co-cultured with primary kidney 
epithelial cells for 2 days in a transwell setup. Il10 expression is significantly higher (p 
<0.05) in RAW cells exposed to ADPKD epithelial cells when compared to NHK-
exposed or naïve RAW cells. (C) THP-1 macrophages were co-cultured in a transwell 
setup with ADPKD epithelial cells for 2 days. The expression of CCL13 (M2 marker 1) 
was upregulated significantly over baseline. (D) THP-1 macrophages were co-
cultured with ADPKD epithelial cells in a transwell setup for 2 days. The expression 
of CCL22 (M2 marker 3) was upregulated significantly over baseline. B-D were 
analyzed using quantitative RT-PCR. 
A B 
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Soluble factor(s) secreted by PKD cells are responsible for promoting M2-
like macrophage polarization.  
 In the THP-1 co-cultures, transwells were used in order to ensure that only 
macrophage transcripts were analyzed. A cell culture well insert was used to 
separate the macrophages (seeded on the bottom plate) from the epithelial cells 
(seeded onto the insert). The insert has a membrane that allows free flow of 
soluble macromolecules but does not allow cell contact. These results indicate 
that polarization of macrophages by cystic epithelial cells is due to one or more 
soluble factors. 
 To determine whether physical contact between the epithelial and 
macrophage cells was necessary for PKD cell stimulated M2-like polarization, 
conditioned media (CM) taken from plated primary ADPKD or NHK cells was 
used to treat macrophage cells. Using this technique we were able to analyze 
both mouse cells (RAW264.7) and a human macrophage cell line, THP-1 cells. 
Treatment of RAW cells with ADPKD cell CM led to a significant increase in M2-
related genes Arg1, Il10, Fn-1 and CCL22 when compared to cells treated with 
NHK conditioned media or those receiving control treatment (Figure 2.4 (A, D) 
and data not shown). Similarly, ADPKD CM treatment of THP-1 cells resulted in 
M2-related gene upregulation comparable to that observed in RAW cells (Figure 
2.4 (B, C)). There was no significant change in M1-associated markers Il6 or 
iNos (Figure 2.4 (A)).  
  




Figure 2.4: The MΦ polarizing effect of ADPKD cells is transmitted through CM.  
(A) RAW macrophages were treated with ADPKD CM for 18 hours and end-point PCR 
was run to look at polarization markers. CM-treated macrophages had a distinctly 
different expression profile when compared to cells exposed to IFNγ (M1) or IL-4/IL/13 
(M2). (B) THP-1 macrophages were were treated with ADPKD CM for 18 hours. Il10 
expression is significantly higher (p <0.05) in THP-1cells exposed to ADPKD CM naïve 
RAW cells. (C) THP-1 macrophages were were treated with ADPKD CM for 18 hours. 
The expression of Fn-1 (M2 marker 2) was upregulated significantly over baseline. (D) 
RAW macrophages were exposed to ADPKD CM for 18 hours. The expression of CCL22 
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Freezing or boiling the media had little effect on the polarization effect (data not 
shown). Collectively, these data indicate that soluble, heat-stable factor(s) 
secreted by ADPKD cells are responsible for the polarization of macrophages. 
ADPKD cell secreted factors can polarize non-naïve macrophages.  
 Since macrophages that are recruited to the kidney in injury states have 
been shown to take on an M1 state, at least initially, the effects of cyst cell 
factors on non-naïve macrophages was assessed. To accomplish this, ADPKD 
cells were co-cultured with RAW cells that had been first polarized to M1 or M2 
by treatment with either IFN-γ or IL-4/IL-13, respectively. For M1 macrophages, 
co-culture with ADPKD cells resulted in robust induction of Arg1 and a 
diminishment in the M1 marker Il6 (Figure 2.5, lane 4). For M2 macrophages, 
ADPKD co-culture enhanced Arg1 and dramatically reduced Mrc1 induction 
(Figure 2.5, lane 6). These results indicate that ADPKD cells can promote M2-
like conversion of polarized, as well as naïve, macrophages and suggest that 
renal tubule cells may promote phenotypic conversion of previously polarized 
macrophages in vivo. 
  




MΦ Treatment: ADPKD 
co-culture 




Arg1 strongly é strongly é strongly é strongly ê 




Mrc1 no change slightly é  strongly é  strongly ê  
Fn1 not observed strongly é not observed not observed 
CCL13 strongly é not observed not observed not observed 
CCL22 slightly é slightly é not observed not observed 
iNos strongly ê slightly ê strongly ê strongly é 
Il6 strongly ê strongly ê strongly ê strongly é 
Figure 2.5: Previous MΦ stimulations can be reversed by the presence of 
ADPKD factors. Semi quantitative RT-PCR of the indicated mouse gene 
transcripts from lysed cell samples following 18 h culture of RAW macrophages 
with media (lane 1), with ADPKD cells (lane 2), or following treatment with either 
IFNγ (lanes 3-4) or IL-4 and IL-13 (lanes 5-6) for 18 h prior to either no further 
treatment (lanes 1-3 and 5) or a secondary treatment with ADPKD cell  
co-culture for 3 d (lanes 4 and 6). 
 
Table 2.1: Summary of markers investigated in treated macrophages. This table 
is a summary of which markers were upregulated or downregulated, and to what 
relative extent, in the previous figures. Mrc1 is highlighted to emphasize the 
difference in expression levels between classically M2-activated macrophages and 
ADPKD-activated macrophages. 
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4. Discussion 
 The studies in this chapter demonstrate that most macrophages in 
ADPKD, ARPKD, and mouse cpk kidneys express M2-like markers. Thus, M2-
like macrophages are present regardless of the underlying genetic abnormality. 
Further, the in vitro experiments indicate that soluble molecules secreted by the 
cyst cells drive this differentiation. It should be noted that the expression profile of 
NHK and ADPKD exposed cells is similar but more pronounced with ADPKD cell 
exposure. While these isolated “normal” cells are not cystic, their harvest likely 
provides stresses to the cells. It is relevant that abundant M2-like macrophages 
are not found in NHK. The fact that NHK cells also elicit a response from 
macrophages indicates that the polarizing signal originating from the epithelial 
cells is not due to a mutation per se, but rather to a state of injury or stress that 
the cells are experiencing. This theory is further supported by the observation 
that PKD cells all elicit some type of macrophages response, some stronger than 
others yet still identical, despite the fact that the disease-causing mutations are 
different in each sample. Therefore, the data presented in this chapter shows that 
the state of chronic injury induced by gradual and constant cyst expansion exerts 
an influence on infiltrating macrophages, resulting in a similar yet distinct 
polarization state to that found in acute injury models. 
 Macrophages can express a variety of genes based on their 
microenvironment, thus leading them to be loosely grouped, as discussed in 
chapter 1. In fact, macrophage phenotypes may exist as a continuum, rather than 
	   40	  
discrete steps. The exact function of all of the different expression profiles is 
unknown and most likely depends on the organ and disease in which they are 
found. 
 While the expression profile of macrophages in vitro does not always 
correlate to the observed macrophage function in vivo, there are often similarities 
that can be observed between the two. Often, the expression profile of immune 
cells in vitro can be helpful in directing researchers to examine previously studied 
similar profiles. For instance, though there is no human equivalent to Arg1 
expression in mouse macrophages, it is a meaningful and reliable marker that 
indicates an M2-like state, and often the loss of its expression correlates with a 
leaning towards an M1 state. Similarly, and perhaps more importantly, the 
expression of the M2 cytokine IL-10 has been extensively studied both in vitro 
and in vivo. Though in vivo studies rarely exactly recapitulate in vitro findings, 
observations made in cell culture have strongly correlated with those made in 
animal models and human patients with regards to IL-10. 
 The significance of IL-10 in disease was discussed extensively in Chapter 
1, but due to the expression profile laid out in this chapter, a short summary 
would be useful. Essentially, in most cases, the loss of Il10 expression or the 
absence of M2 macrophages leads to a slowed healing process and prolonged 
repair phase. Many studies indicate that the presence of M2 macrophages is 
essential for the formation of new tissue and the recovery of injured yet functional 
tissue. This is opposed to the presence of M1 macrophages, which play a critical 
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role in the case of infection or presence of pathogens. The extended presence of 
these M1s, however, is detrimental to recovery due to uninhibited inflammation. 
IL-10 plays a critical role in inhibiting inflammatory processes and in somehow 
contributing to epithelial proliferation. Examination of the role of this cytokine in 
PKD will be performed in chapter 3. 
 As stated above, in most cases of injury, this process is necessary for 
recovery. However, in the case of chronic injury in which the source of injury is 
never removed, and specifically in the case of a hyperproliferative environment 
such as PKD, the presence of macrophages which are secreting possible 
proliferative cytokines could be a confounding factor of disease progression.	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Chapter Three 




 The pathological process of cyst enlargement in PKD is hypothesized to 
be largely the result of aberrant proliferation of cyst-lining epithelial cells, though 
fluid secretion also plays a role 106, 107. The mechanisms that underlie the 
hyperproliferative phenotype of cyst cells are complex, but defects caused by 
mutations in PC1 and/or PC2 have been shown to be the primary drivers of the 
proliferation 108,107. In particular, mutant collecting duct epithelial cells, which are 
the origin of most cysts in human ADPKD and ARPKD, show abnormal 
proliferative responses to cAMP 30, 107 109. In the collecting duct, cAMP production 
is primarily driven by vasopressin in vivo 110, 111. Other signaling abnormalities 
also are believed to contribute to proliferation, including responses to EGF, TGF, 
and Ca2+ 112, 113. 
 The proliferative tendency of these cystic cells has been the subject of 
much research, as agents that target this process are predicted to ameliorate 
disease. In fact, targeting proliferation has been shown to be a potentially 
successful approach for PKD therapy. Drugs that reduce cell proliferation, such 
as inhibitors of Src kinase, Erb-B1 (EGFR), mTOR, and MEK have all been 
shown to reduce cystic disease in mouse models 19, 27, 112, 114. Additionally, a Raf 
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inhibitor was found to inhibit in vitro cAMP-dependent cyst proliferation and 
growth in human ADPKD cells 19, 107. Antagonists of the V2-vasopressin receptor, 
which is highly expressed in collecting duct, also reduces cyst expansion in 
animal models of disease 110, 111. One such antagonist, tolvaptan, has also 
recently been shown to have efficacy in slower cyst expansion in patients with 
ADPKD 18, 115. Unfortunately, tolvaptan showed hepatic toxicity and other side 
effects that prevented its FDA approval. Thus, new strategies that target 
proliferation are needed. 
 As previously noted in Chapter 1, macrophages have been found to 
promote proliferation in a multitude of diseases. Specifically, in kidney injury 
models macrophages, especially M2-like macrophages, can promote proliferation 
as a part of the healing process. If these macrophages are removed, recovery is 
slower due to decreased proliferative capability, and the addition of M2-
programmed macrophages promotes renal cell proliferation and accelerates 
recovery from injury 56, 72, 77, 80. As described in chapters 1 and 2, M2-like 
macrophages are present in both human PKD and animal models of disease. 
Also, depletion of macrophages from animal models of disease results in slowed 
disease progression and lower proliferation 4, 37. In this chapter, macrophages are 
shown to directly stimulate proliferation of cyst epithelial cells. Importantly, 
exposure of macrophages to cyst epithelial cells “programs” them, promoting 
differentiation to a phenotype that is particularly effective at promoting cyst cell 
proliferation. Further, we show that autocrine macrophage signaling of a 
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regulatory cytokine, IL-10, is critical for this programming step. These data lead 
me to conclude that a vicious cycle exists to promote disease progression: cystic 
epithelial cells promote the M2-polarization of macrophages and M2 polarized 
macrophages promote cystic epithelial cell proliferation, thereby promoting cyst 
growth.   
 
2. Methods 
 Media: PKD_A media is DMEM/F-12 (Cellgro 15-090-CV, Mediatech Inc.; 
Manassas, VA) supplemented with 5% FBS, 15 mM HEPES, 5 μg/ml insulin, 5 
μg/ml transferrin, 5 ng/ml ITS, P/S, and 5 ng/ml EGF. XVIVO-10 (Bio Whittaker, 
Walkersville, MD) contains L-glutamine, gentamicin, phenol red, P/S, and 10 mM 
HEPES buffer. Minimal media is DMEM (D6429, Sigma-Aldrich) with P/S and 
0.1% FBS. Maximal media is DMEM with P/S and 10% FBS. Basal media is 
DMEM with P/S and containing no FBS. ATP Depletion media is (glucose-free 
DMEM [11966, Life Technologies] containing 2% FBS,10 mM deoxyglucose and 
Pen/Strep. Bone Marrow (BM) media is DMEM containing 10% HIFBS, 2 mM L-
glutamine, Pen/Strep, and 10% L-cell Conditioned Media. L929 media is DMEM 
(D6429; Sigma) media containing the following; 10% HIFBS (S11550,Atlanta 
Biologicals), 2mM L-glutamine, and  Pen/Strep.   
 Conditioned media (CM): ADPKD CM was made by plating 3.7 x 106 
ADPKD cells into a 15 cm plate. Media was replaced after 24 hours with 20 ml 
XVIVO-10 (Bio Whittaker, Walkersville, MD) and collected after 3 days. The 
media was then spun down at 600 RCF for 5 minutes, aliquotted, and stored at -
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80°C until needed. LCCM (L-cell Conditioned Media) media is obtained by 
seeding L929 cells at 50% confluency in a 15 cm dish and allowing them to grow 
for 5 days in 25 ml of media. After 5 days the media is collected, spun down at 
600 RPM for 5 minutes, filtered at 0.25 µm, and stored at -20°C. 
 Cells: PKD_A cells 116 (immortalized proximal tubule cell line) were used in 
proliferation assays because they respond to programmed conditioned media, 
though they are incapable of programming macrophages themselves. PKD_A 
cells were carried and used for 20 passages before being replaced, and were 
checked periodically for morphological or division abnormalities and changes. 
RAW cells were maintained in DMEM media containing 10% FBS, 200 uM L-
glutamine, and Pen/Strep. THP-1 monocytes were maintained in RPMI-1640 
media (R8758, Sigma-Aldrich, St. Louis, MO) containing 10% FBS, 200 μM L-
glutamine and Pen/Strep. 
 ELISA: Macrophages were cultured for 24 hours before treatment, after 
which conditioned media were collected and centrifuged, stored at 4°C until all 
samples had been collected. The supernatant was analyzed for IL-10 using either 
the Mouse IL-10 ELISA Ready-SET-Go kit (eBioscience, cat #88-7105) in the 
case of RAW 264.7 cells or the Human IL-10 ELISA Ready-SET-Go kit 
(eBioscience, cat #88-7106) in the case of THP-1 cells. 
 Neutralizing Assays: Neutralization of mouse IL-10 was carried out using a 
mouse-specific anti-IL-10 antibody obtained from eBioscience (cat #16-7102-85) 
or the IgG isotype control (cat #14-4714-82). At the appropriate time, antibodies 
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were added directly to both the counted and designated macrophages cells in 1.5 
ml eppendorf tubes as well as to the wells containing primary ADPKD cells 
without any pre-incubation period. The antibodies, contained in the media, were 
only removed once the experiment was collected for analysis. 
Proliferation Assays: 
  BMDM. Transwell proliferation assays were conducted with primary 
ADPKD cells plated at a density of 2.0 x 105 cells per well in a flat-bottomed 6-
well plate. Cells were incubated for 24 h then placed into an ATP depletion media 
for 24 hours, after which the PKD cells were placed into 2 ml of minimal media or 
maximal media. Transwells (0.4 μm) were then placed into the wells and BMDMs 
were plated onto the transwell in 1.0 ml of minimal media at a density of either 
2.0 x 105 or 5.0 x 105.  Mouse IL-10 (R&D) was added to both the top and bottom 
of the transwells at a final concentration of 20 µg/ml when appropriate. Once 
combined, cells were incubated for 3 days, after which the transwell was 
removed and the media was aspirated. The PKD cells were then collected into 
100 µL of 2% PFA in PBS and stored at 4°C for 4-6 days, after which they were 
counted on a hemacytometer. 
 RAW 264.7. Direct co-culture proliferation assays were performed using 
RAW cells and an anti-IL-10 antibody (R&D) or IgG isotype control (R&D). 
ADPKD cells were plated at a density of 5.0 x 104 cells per well in a flat-bottomed 
6 well dish, incubated for 24 hours, switched into ATP depletion media for 24 
hours, and then RAW cells were plated on top at a density of 5.0 x 104 in minimal 
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media. Mouse-specific IL-10 neutralizing antibody (R&D) or the IgG control (R&D) 
was added to the appropriate wells at a concentration of 1 μg/ml. These co-
cultures were collected in 2% PFA/PBS after 3 days, stored at 4°C for 4-6 days, 
and then manually counted on a Leica microscope (DMILFluorescence 
Microscope) using a hemacytometer. ADPKD and RAW cells were readily 
distinguished by morphology. 
 MΦ CM. All other proliferation assays were carried out without direct 
macrophage and ADPKD cells contact during the proliferation phase. PKD_A 
cells were plated in flat-bottomed 24-well plates at a final density of 1.2 x 104 
cells. They were switched into ATP depletion media after growing overnight. After 
24 hours, the media was replaced with programmed media, minimal media, or 
maximal media. All proliferation assays were collected after 3 days. The media 
was aspirated and the cells were washed once with 1X PBS then frozen at -80°C 
for 18-24 hours. Proliferation was then assayed using the Cyquant Cell 
Proliferation Assay Kit from Life Technologies, measuring fluorescence using a 
Synergy 2 from Biotek (BioTEK Instruments, Inc., Winooski, VT). Programmed 
media was made using RAW cells plated at a density of 1.0 x 106 or THP-1 cells 
plated at a final density of 2.0 x 106, placed in XVIVO or ADPKD CM (made in 
XVIVO) for the appropriate amount of hours (usually 18), and then switched into 
basal media for 24 hours. The programmed basal media was then collected and 
spun at 600 x g for 5 min, brought up to a final concentration of 0.1% FBS, and 
placed onto ATP-depleted PKD cells.  The addition of inhibitors or cytokines took 
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place after the serum adjustment but before the media was placed onto the PKD 
cells. 
 Mice: 
 Strains and genotypes: All animal use was approved by the IACUC. 
Mice were housed according to LAR guidelines. Both the cpk 117 and Il10 
(Jackson Laboratories, C.129P2(B6)-Il10tm1Cgn/J) mice were bred into and carried 
in a Balb/C background. All animals used for the IL-10 study were provided with 
Ciprofloxacin, supplementing their drinking water at a final concentration of 200 
mg/l. This was done to prevent the early onset of intestinal irritation and 
subsequent severe bowel disease that occurs in Il10 null 118, 119 mice. In addition, 
all breeder mice were carried as double heterozygous pairs (cpk +/-: Il10 +/-) as 
cpk null mice die before sexual maturity and Il10 null mice were only able to birth 
one litter before succumbing to bowel disease. Kidneys were collected and 
placed into RNAlater or formalin once blood had been collected from the thoracic 
cavity. All mice used for kidney collection were sacrificed at PN day 10. Sera was 
collected and stored for BUN analysis, the right kidney was collected and placed 
in RNAlater for RNA or protein analysis, and the left kidney was collected and 
placed in formalin for sectioning and IHC analysis. 
 Isolation of mouse Bone Marrow Derived Macrophages (BMDM): 
Balb/C mice were sacrificed and bone marrow was harvested from the tibias and 
femurs of male mice aged 6-8 weeks. Bones were removed from the mice, 
cleaned, stripped of all tissue with the use of forceps, placed in cold PBS, and 
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rinsed with 70% ethanol. Ends were cut from each bone and marrow was 
extracted using sterile technique with a 21 G needle and sterile PBS into a 50 ml 
conical tube. Cells were centrifuged at 4°C and 1200 RCF for 5 minutes, 
resuspended, and then plated at a density of 5.0 x 106 cells per plate in sterile 
non-TC coated dishes. Cells were plated in 10 ml of BM media and incubated at 
37°C in 5% CO2 for 3 days, after which 4 more ml of BM media were added and 
the cells were incubated for another 3 days (6 days total). After 6 days, all non-
adherent cells were removed, and the adherent cells (macrophages) were placed 
into 5 ml of cold PBS and incubated at 4°C for 30 minutes. After incubation, the 
cells were scraped from the dish and centrifuged at 1200 RCF for 5 min. Cells 
were re-suspended in L929 media and the desired number (see Proliferation 




Macrophages promote cyst cell proliferation. (co-culture, transwell; RAW, 
THP-1, and primary BMDM) 
 To assess effects of macrophages on PKD cyst cell proliferation, primary 
ADPKD cells were cultured with a mouse macrophage cell line (RAW264.7 cells). 
Co-culture of the cyst cells with macrophages induced epithelial cell proliferation 
(Figure 3.1), as assessed by an increase in ADPKD cell number 4.  
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Figure 3.1: Macrophages elaborate soluble factor(s) that promote ADPKD cyst cell 
and NHK proliferation. (A) Primary ADPKD cyst epithelial cells (kidney K354) 
or (B) NHK cells (kidney K342) were incubated with low (1% FBS) or high (10% FBS) 
serum media or co-cultured with naïve RAW macrophages suspended in low serum 
media. After 72 h, cells were collected and fixed and the number of ADPKD cells 
determined by counting. The data are representative of four similar experiments for 
ADPKD cells from different kidneys. (C and D) Cell-impermeable transwell inserts were 
placed in tissue culture wells previously seeded with primary ADPKD (C) or NHK (D) 
cells (Kidneys K338 and K343, respectively). Naïve RAW macrophages in low serum, 
low serum media alone, or high serum media were placed in these inserts, and the 
kidney cells were collected after 72 h and counted (C) or relative number of cells 
determined by lysis and incubation with CyQUANT® GR dye (D). Data are presented as 
mean ± SEM. *, **, and *** denote P<0.05, P<0.01 and P<0.001, respectively. 
 
Taken from Swenson-Fields4 et al. 
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Similar results were observed when primary bone marrow-derived mouse 
macrophages (Figure 3.5) or human macrophage-like cell line (Figure 3.1) were 
incubated with the primary PKD cells. Additionally, media taken from plated naïve 
macrophages, when placed on primary ADPKD cells, increased their proliferative 
capacity over that of control (normal media) treated primary ADPKD cells. 
Macrophages promote ADPKD cell proliferation. 
 
Cyst cells promote development of pathogenic (pro-proliferative) 
macrophage phenotype in PKD.  
 As shown in Chapter 2, PKD cyst cells elaborate factor(s) that promote 
differentiation of macrophages to a distinct M2-like phenotype, defined by 
increased expression of Arg1, Il10 and Fn1 and the absence of M1-associated 
cytokines such as Il6 and iNos. While markers are useful tools to define 
differentiation, it is unknown whether this differentiation state influences 
macrophage function in PKD. A particularly relevant question is whether this 
differentiation state affects the ability of macrophages to promote cyst cell 
proliferation, since that activity would promote disease progression. 
 To address this hypothesis, macrophages were exposed to PKD cell 
secretions by incubation with ADPKD conditioned media (“programmed”), and 
their subsequent ability to promote PKD cyst cell proliferation was measured. The 
experimental design is shown in Figure 3.2.  
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Figure 3.2: Model of CM Proliferation Assays. Primary ADPKD cells were 
seeded in their normal media overnight. Media was then replaced with 
XVIVO10 media and collected after 3 days. This is referred to as ADPKD CM. 
The ADPKD CM is then placed onto plated RAW or THP-1 macrophage cells 
for 18 hours to program the macrophages. After 18 hours, the ADPKD CM is 
replaced with 0.1% media (minimal media) for 24 hours. After 24 hours, the 
meida is collected off of the macrophages cells. This is referred to as MΦ CM. 
The MΦ CM is then placed onto PKD cells for 3 days, after which point the 
treated PKD cells are collected and proliferation is assayed. 
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ADPKD cells were seeded at a specific concentration (see Methods) and allowed 
to grow in their own media overnight. They were then switched into XVIVO or 
RAW media, depending on the experiments, for 72 hours, at which point the 
media was collected and stored (CM). This CM was then used to program 
macrophages for an appropriate amount of time (usually 18 hours), after which 
they were switched into basal media. After 24 hours, this media was collected 
and placed onto PKD-A cells, which were collected and assayed after another 72 
hours. 
 As illustrated in Figure 3.3, mouse RAW macrophages programmed by 
ADPKD CM secreted factors that promoted cyst cell proliferation. Similar results 
were observed using human-derived macrophages (from THP-1 cells). These 
data indicate that cyst cells and macrophages are capable of reciprocal signaling 
in PKD: cyst cells promote differentiation of macrophages to an M2-like state, a 
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Figure 3.3: ADPKD CM induces a pro-proliferative MΦ reaction. PKD-A cells 
incubated for 72h with CMs obtained from (A) RAW macrophages or (B) THP-1 
macrophages previously cultured alone (No program) or from those pre-
programmed by incubation with ADPKD CM. FBS (0.1%) was added to CMs prior 
to assay. This experiment was repeated using CMs from ADPKD cyst cells 
prepared from more than 5 other kidneys with similar results. Data are presented as 
mean ± SEM. Asterisks ** denote P<0.01, respectively. 
 
A B 
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The M2 cytokine IL-10 is required for development of the pathogenic 
macrophage phenotype.  
 As discussed above, the pathogenic macrophage in PKD expresses a 
number of known M2-like markers. Of these markers, those that are critical for 
differentiation may be therapeutic targets for PKD. To identify crucial markers, 
attention was initially focused on IL-10, a regulatory cytokine that we have shown 
is upregulated in programmed macrophages (Chapter 2). Intriguingly, a recent 
report suggested that IL-10 expressing macrophages promote myoblast 
proliferation in the context of muscle injury 48. 
 To determine whether IL-10 was relevant to the pro-proliferative 
macrophage, the timing of induction of the pro-proliferative phenotype was 
compared to induction of IL-10 in RAW cells. Macrophages were exposed to 
ADPKD CM for increasing amounts of time, with the shortest collection occurring 
after 30 minutes and extending through 24 hours (Figure 3.4). Media was added 
in decreasing order, so that all of the media was collected from programmed 
macrophages at the same time and placed onto PKD-A cells. As shown in 
Figure 3.4 (A and data not shown), significant macrophage pro-proliferative 
activity appeared after ~12 h of programming by ADPKD CM and was present 
through 24 h. 
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Figure 3.4: IL-10 secretion by MΦ correlates with the appearance of the pro-
proliferative MΦ phenotype. (A) RAW macrophages were programmed for increasing 
time periods with ADPKD cyst cell CM, or were incubated with media alone.  Media 
was collected on ice and cells were subsequently washed and incubated with basal 
media for an additional 24 h to produce either Programmed or Unprogrammed CM, 
which were then assayed for effects on proliferation of PKD-A cells. Data is plotted as 
fold-change relative to baseline proliferation values determined from PKD-A cells 
grown in 0.1% FBS in parallel. (B) Macrophage-produced IL-10 levels were measured 
in the ADPKD cyst cell CM used for programming described in (A), which was collected 
and stored on ice, by the use of an ELISA kit specific for mouse IL-10. (C) The levels of 
human IL-10 were measured in ADPKD cyst cell CM used for programming THP-1 
macrophages for increasing time periods.  The levels of human IL-10 present in 
ADPKD cyst cell CM prior to programming and after 30 m of programming, as well as 
those levels present in macrophages incubated in parallel in media only (data not 
shown) were below the detection limits (30 pg/ml) of the ELISA kit used. 
A B 
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To examine IL-10 induction, RAW cells or THP-1 cells were treated with 
conditioned media as mentioned above, and media not used for proliferation 
assays was collected and stored in siliconized tubes at 4°C for analysis. ELISA 
plates were coated with IL-10 capture antibody overnight to maximize sensitivity 
and then media was added and the assay performed. As shown in Figure 3.4 
(B), induction of significant IL-10 (~200 pg/ml) occurred by 8 h and increased 
throughout the programming time course. The induction of human IL-10 similarly 
required ~8 h (Figure 3.4 (C)). These data indicate that IL-10 induction preceded 
induction of the proliferative phenotype, suggesting that IL-10 could potentially 
contribute to its development. 
 To investigate the contribution of IL-10 directly, an IL-10 neutralizing 
antibody was used. ADPKD cells were seeded and grown overnight, at which 
point they were rinsed and placed into minimal media. RAW macrophages were 
brought up and counted in minimal media (0.1% media), at which point the 
correct treatment (IL-10 antibody or isotype control) was added. The treated and 
counted macrophages were then placed on top of the ADPKD cells and the cells 
were co-cultured for 72 hours before harvesting and fixing. The cells were then 
counted with the identity of the wells blinded to the evaluator. The distinct 
morphologies of RAW cells and ADPKD cells facilitated counting. The experiment 
was repeated twice with the appropriate number of technical replicates. As 
shown in Figure 3.5, anti-IL-10 but not the IgG isotype control significantly 
inhibited macrophage-stimulated PKD cell proliferation. Since mouse 
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macrophages were used in this experiment and mouse IL-10 does not have 
cross-species activity, it is most likely that IL-10 is affecting the macrophage 
phenotype rather than the epithelial cells directly. To formally address this 
possibility, mouse IL-10 was added to PKD cells directly and proliferation 
assessed (Figure 3.5 (B)). As illustrated, IL-10 does not have a pro-proliferative 
effect on PKD cells. Similar experiments were performed with human IL-10 
(Figure 3.5 (C)) with comparable results, that is, human IL-10 did not stimulate 
PKD cyst cell proliferation. 
 To assess the contribution of IL-10 in primary, non-immortalized cells, 
bone marrow-derived macrophages (BMDM) from wild-type (WT) or IL-10 
knockout (IL10KO) mice were incubated with ADPKD cyst cells and effects on 
proliferation measured. As shown above, WT BMDM stimulated proliferation 
(Figure 3.6); however, IL10KO macrophages showed no pro-proliferative activity. 
Strikingly, addition of exogenous IL-10 to the IL10KO macrophages completely 
rescued the pro-proliferative phenotype. These data indicate that IL-10 is a 
critical, autocrine regulator of pathogenic macrophage differentiation in PKD. 
 To determine whether IL-10 was sufficient for development of the 
pathogenic, pro-proliferative macrophage phenotype, macrophages were 
programmed with IL-10 alone. Interestingly, exogenous IL-10 alone did not 
induce the pro-proliferative phenotype (Figure 3.6 (D)). These data suggest that, 
while IL-10 is necessary, it is not sufficient for pathogenic macrophage 
differentiation in PKD. 
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Figure 3.5: IL-10 is necessary for the proliferative MΦ phenotype but is not the 
proliferative factor acting upon the epithelial cells. (A) Proliferation assay of 
ADPKD cyst cells directly cocultured with RAW MΦs in the presence of 0.1% FBS and 
either a mouse-specific IL-10 neutralizing antibody (2 ug/ml), a non-immune IgG control 
antibody (2 ug/ml) or no additions (none).  These cells also were incubated alone in 
parallel with 0.1% FBS to measure baseline proliferation, or 10% FBS to measure 
stimulated proliferation. After 72h, cells were trypsinized, fixed and the numbers of 
ADPKD cells determined by direct counting.  This experiment was repeated using 
ADPKD cells from more than 5 different kidneys with similar results. Data are presented 
as mean ± SEM. (B) Proliferation assay of ADPKD cyst cells incubated with either 0.1% 
FBS media  (Control) or the same media containing mouse IL-10 at the indicated 
concentrations. After 72h, cells were collected and assayed for relative proliferation 
following lysis and incubation with CyQUANT® GR dye. (C) Proliferation assay of ADPKD 
cyst cells carried out similarly and in parallel with assay described in (B) to test the direct 
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Figure 3.6: IL-10 is necessary for the proliferative MΦ phenotype, which can be 
restored with the addition of exogenous IL-10. Proliferation assay of ADPKD cyst 
cells indirectly cocultured (in Transwells) with BMDMs isolated from either (A) wild-type 
(WT) or (B) IL-10-deficient (IL-10-/-) mice.  Cocultures were seeded in 0.1% FBS.  ADPKD 
cyst cells also were incubated alone in parallel with 0.1% FBS. After 72h, cells were 
trypsinized, fixed and the numbers of ADPKD cells determined by direct counting. Data are 
presented as mean ± SEM. (C) Proliferation assay of ADPKD cyst cells indirectly 
cocultured (Transwells) with BMDMs isolated from IL-10-/- mice in the presence or 
absence of added recombinant mouse IL-10 (20 ng/ml) for 72h. ADPKD cyst cells also 
were incubated with IL-10 or 0.1% FBS only. Cocultures were seeded in 0.1% FBS. (D) 
Proliferation assay of ADPKD cyst cells incubated with CMs from THP-1 MΦs previously 
cultured alone (None), with ADPKD cyst cell CM or with human IL-10 in a programming 
step, prior to washing and a 24 h incubation in basal media. FBS (0.1%) was added to 
CMs prior to addition of ADPKD cells. In parallel, cells were also incubated with 0.1% and 
10% FBS, to measure baseline and stimulated proliferation, respectively. After 72h, cells 
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Heterozygous loss of IL-10 may slow disease progression in a rapid mouse 
model of PKD.  
 To assess the potential relevance of IL-10 in vivo, IL10KO mice were bred 
to cpk mice. IL10KO mice are known to develop inflammatory bowel disease 118, 
119, a phenotype that complicated breeding strategies, since these mice were 
rarely successful in mating. Also, generation of Il10-/-; Cys1cpk/cpk mice did not 
follow expected Mendelian frequencies, suggesting a deleterious effect of the 
presence of homozygous mutants in both loci on development. Thus, it was not 
possible to examine effects global IL10KO on cystic disease in this model. 
 However, cystic mice that were heterozygous at the IL-10 locus (Il10+/-; 
Cys1cpk/cpk) were generated and analyzed. Notably, cystic IL-10 heterozygotes 
showed a statistically significant decrease in kidney size (2 kidney/bodyweight 
ratio) compared to to IL-10 wild-type mice (Figure 3.7 (C)). Histologic analysis 
reveals a slight decrease in cystic area, but the results were not statistically 
significant (Figure 3.7 (A, B)). Similar findings were present in assay for renal 
function (BUN) (Figure 3.7 (E)). That is there is a small but not statistically 
significant decrease, also with a p ~0.1. While these data are not conclusive, they 
suggest a possible ameliorative effect of diminished IL-10 on cystic disease. 
 
  




Figure 3.7: The effect of genetic depletion of Il10 in a rapid cystic mouse model. IHC 
image of an (A) Il10+/- and a (B) WT control, both mice on the cpk/cpk background. This was 
repeated with 6 mice of each genotype, and these are representative of the two extremes 
from each group. (C) Mice were weighed and then the kidneys removed and weighed 
immediately after death. (D) Average cortical cystic index (cortical cyst area/total cortical 
area) was calculated from measurements of kidneys from animals on both backgrounds. 6 
mice were studied for each genotype. (E) Blood was harvested upon euthanasia, spun 
down, and the isolated sera was frozen at -80 °C. BUN were measured as previously 
described, using a colorimetric assay. 
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4. Discussion 
 As previously discussed, IL-10 has been implicated as an important factor 
in the recovery of injury, caused either by disease or trauma, in many organs. 
Macrophages that are present during the repair and regenerative phase are 
typically classified as M2 macrophages and are commonly characterized by their 
elevated expression of IL-10. In a study focusing on muscle injury recovery, it 
was found that IL-10 levels were elevated from three to seven days post-injury. In 
fact, the macrophages in vivo did not reflect a clear M1 or M2 phenotype, but IL-
10 was the only cytokine and macrophage marker clearly elevated after the injury 
occurred, indicating that it played a key role in the healing process 120. In other 
studies of general wound healing, it was found that M2 macrophages dominated 
in response to injury and were the driving immune forces of tissue formation. The 
depletion of macrophages (characterized predominantly as M2s) during the 
healing phase delayed formation and maturation of new tissue, and actually led 
to detectable epithelial apoptosis 120. During the characterization of these 
macrophages, IL-10 was found to be noticeably elevated, while there was no 
detectable change in Ym1, Mrc1 or Retnla, classic M2 markers, which will be 
discussed in further depth in the next chapter. 
 Additionally, in research focused on spinal injury, which recovers in a 
pattern distinct from general wound healing, IL-10 was again found to be 
necessary during the proliferative phase to facilitate tissue remodeling 120, 121. 
While persistent macrophage presence is recognized as a hallmark of chronic 
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injuries, these studies found that the macrophages that lingered throughout the 
proliferative and remodeling phases (one week to months) were M2-like. They 
secreted elevated levels of IL-10, CCL17, CCL22, and CCL18, all of which have 
been shown to promote production of extracellular matrix components and 
growth factors. The studies further found that the misregulation of macrophages, 
specifically the lack of IL-10 induction, played a role in extended and persistent 
spinal cord injury. Even more convincingly, skewing or boosting the macrophage 
phenotype to the M2b and M2c phenotypes (activated microglial cells) via 
injection of MCP-1, MIP-1α, or IL-1β adjacent to the injury site restored the 
proliferative phase of healing and led to an improved recovery 122. 
 As these varied studies show, IL-10 production and the macrophage 
phenotype that it leads to are both important in the healing process. However, in 
a disease such as PKD, the injury is chronic and persistent, worsening as time 
goes on. Further, the cystic cells have an intrinsic hyperproliferative phenotype. 
Hence, when the injury is unresolved, the presence of cells (in this case 
macrophages) that enhance and promote the proliferative phenotype of epithelial 
cells would be predicted to worsen the disease and accelerate progression. 
Consistent with this hypothesis, we and others have shown that depletion of 
macrophages from PKD mouse models diminishes cyst cell proliferation and 
slows disease progression. In this chapter, the data presented suggest that these 
macrophages take on a pathogenic phenotype that relies on IL-10 production and 
its autocrine effects. This cytokine, while often associated with anti-inflammatory 
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macrophage regulation, may have deleterious effects in PKD, indirectly 
promoting cyst growth and disease progression. 
  
	   66	  
Chapter Four 
IL-10 Signals in a Distinct and Autocrine Fashion to Induce a Pro-
Proliferative Macrophages Phenotype 
 
1. Introduction 
 IL-10 is an important cytokine that was originally identified as a potent 
inhibitor of Th1 polarized T cells 123 and has subsequently been shown to be a 
critical endogenous anti-inflammatory molecule affecting T cells as well as 
macrophages, dendritic cells, B cells, mast cells, and some epithelial cells 124. 
Because of its broad immune effects, IL-10 signaling is known to play a role in a 
number of human diseases, including inflammatory bowel disease, diabetes, and 
rheumatoid arthritis 125-129. IL-10 has also been found to play a role in kidney 
diseases, where its presence can improve recovery from injury or prevent 
inflammation due to obesity or other insults 70. In Chapter 2, IL-10 was shown to 
be expressed in macrophages that infiltrate the cystic kidneys of PKD. Further, 
Chapter 3 demonstrated that this cytokine plays an essential role in generating a 
pathogenic macrophage phenotype in these kidneys, which promotes cyst cell 
proliferation. These findings suggest that modulation of IL-10 function, including 
its production and signaling mechanisms, could be a potential therapeutic 
strategy in PKD. In order to design an effective therapeutic intervention, it is 
critical to understand how IL-10 is produced and is signaling in the context of 
PKD.  
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 IL-10 is expressed in all leukocytes, and its production is tightly controlled 
by a complex regulatory network 124. While many pathways contribute to IL-10 
production in a cell type specific manner, TLR stimulation results in a significant 
upregulation of Il10 in macrophages, particularly that of TLR2/Myd88 and TLR4. 
Ligand binding to other TLRs has also been shown to induce Il10. In addition to 
direct ligand activation of TLRs, it is also possible for TLR-independent IL-10 
stimulation to occur through NOD2 signaling, DC-SIGN, and Dectin-1. These 
signaling cascades are typically triggered by pathogens but TLR-independent 
production of IL-10 can occur because of exposure to other cytokines, such as 
IFNγ and IL-10 itself 130, 131. Studies have revealed putative cAMP response 
elements (CRE) on the IL-10 promoter, indicating a possible regulatory 
interaction with CREB 132, 133. NFκB family members such as RelA and p50 have 
also been associated with IL-10 regulation in LPS-stimulated macrophages 134. 
 The downstream pathways activated by IL-10 are also complex and can 
vary by cell type and numerous co-factors. However, it is widely accepted that 
signal transducer and activator of transcription 3 (Stat3) is activated by IL-10 
receptor signaling. This activation is necessary and sufficient for the observed 
anti-inflammatory, properties and effects of IL-10 49. Importantly, it has previously 
been reported that Stat3 activation is elevated in both mouse models of PKD and 
in human patient samples 135. Moreover, inhibition of Stat3 activation has recently 
been studied as a possible therapy for PKD with promising preliminary results in 
animals, effects that were believed to be due to effects on cyst epithelial cells 136. 
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 In this chapter, the signaling network surrounding IL-10 production and 
function in PKD-polarized macrophages will be examined. The data suggest that 
signals activating NFκB are important upstream signals for the PKD-stimulated 
IL-10 production in macrophages. Also, evidence is presented indicating that 
Stat3 activation is an important downstream element of autocrine IL-10 signaling 
in PKD macrophages. These data suggest that NFκB and Stat3 could be 
potential targets for therapy in PKD. 
 
2. Methods 
Cells, macrophage programming, and proliferation assays were performed as 
described in previous chapters. 
 Western Blotting: RAW or THP-1 cells were seeded in 6-well plates and 
treated with ADPKD CM for the indicated times. Cells were washed once with 1X 
PBS and then harvested in an SDS lysis buffer. Protein concentration was 
determined using Bradford assay (Biorad, #5000006) according the 
manufacturerʼs instruction. Samples for Stat3 detection were processed on a 
12% acrylamide gel at 100 V for 2 h. Samples probed for IL-10 were run on a 
15% acrylamide gel at 120V for 2 h. Samples probed for all other proteins were 
run on 10% acrylamide gels at 100V for 2 h. Protein was transferred to 
nitrocellulose at 30V overnight at 4°C. Membranes were blocked in Licor reagent 
(Licor, P/N 927-40000) for 30 minutes then probed with primary antibodies 
(diluted at 1:1000) obtained from Cell Signaling for 1-2 hours. The following 
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primary antibodies were used: RhoGDI (#2564), Stat3 (#9139), phosph0-Stat3 
(#9131), and IκBα (#4814). After 6X washing with Tris buffered saline with 0.05% 
Tween 20 (TBST), the membranes were probed with appropriate secondary 
antibodies (diluted at 1:15,000) conjugated to near-infrared fluorophores obtained 
from Licor. Probed membranes were scanned and analyzed using the Odyssey® 
(Licor). 
 ELISA: IL-10 was measured in culture supernatants using an ELISA kit 
(eBioscience #88-7104-22, San Diego, CA) according to the manufacturerʼs 
protocol. Media was collected from treated RAW cells at the indicated time 
points, centrifuged at 600 x g for 5 minutes, then stored at 4°C until all samples 
were collected and the assay could be run. 
 Immunohistochemistry: De-paraffinized sections were steamed in 0.01 M 
citrate buffer (pH 6.0) for 20 min (steamer #HS900, Black & Decker, Madison, 
WI). Sections were then incubated in 3% H2O2 followed by serum from the host 
animal in which the relevant secondary antibody was generated. Samples were 
incubated with an CD-163 antibody (Cat. No. CD163-MS-1103, ThermoFisher) or 
phosphor-Stat3 antibody (9145, Cell Signaling) overnight at 4°C. Appropriate 
secondary antibodies (ImmPRESS, Vector Laboratories, Burlingame, CA) were 
then applied for 30 min at room temperature prior to visualization by light 
microscopy. All IHC and Fluorescence Microscopy were done as previously 
described 4. 
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3. Results 
Autocrine IL-10 Activates Stat3 in ADPKD-Programmed Macrophages 
 In the previous chapter, autocrine IL-10 was shown to be required for 
pathogenic macrophage polarization. Since IL-10 is known to activate Stat3 by 
signaling through the IL-10 receptor, Stat3 activation was examined in 
macrophages programmed by ADPKD cells. RAW macrophages were treated 
with ADPKD CM, and Stat3 activation was measured using phospho-specific 
antibodies to pTyr705 Stat3 and Western blot (Figure 4.1 (A, B)). This approach 
revealed two peaks of Stat3 activation: a transient one that peaked at 15 min and 
diminished to near baseline by 1 h and a second one that began ~8-12 and was 
maximal ~18 h. This latter peak roughly coincides with the macrophage 
production of IL-10 (see Chapter 3, Figure 3.4) suggesting this cytokine drives 
this later activation. 
 To confirm that autocrine IL-10 was responsible for the late Stat3 
activation, an IL-10 neutralizing antibody was used. Neutralizing antibody but not 
control Ig blocked STAT3 activation in RAW MΦs in response to recombinant IL-
10 treatment, as expected (Figure 4.1 (C), left panel). Also, the neutralizing 
antibody but not control Ig prevented STAT3 activation by ADPKD CM after 18 h 
(Figure 4.1 (C), right panel). These data indicate that MΦ IL-10 produced during 
programming with ADPKD CM is responsible for the late activation of the STAT3 
pathway in MΦs.  
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Figure 4.1: MΦ derived IL-10 activates autocrine Stat3 signaling.  
A and B. RAW MΦs were incubated with ADPKD CM for increasing, successive time 
periods prior to lysis and immunoblot analyses of total protein using anti-phospho-
STAT3 and anti-STAT3 antibodies for detection of activated and total STAT3, 
respectively. (A) Immunoblot of cell samples collected from 0-60 min. (B) Immunoblot 
of cell samples collected from 1-24 h. NS = non-specific bands, which serve as a 
control for protein loading. (C) RAW MΦs were incubated for 18 h with either mouse 
IL-10 (10 ng/ml), ADPKD CM or media alone, as indicated, in the presence of an anti-
IL-10 neutralizing antibody (αIL10) or equal concentrations of a control antibody (IgG) 
prior to cell lysis. Total protein was subjected to immunoblot analyses using anti-
phospho-STAT3 antibodies, as well as anti-tubulin antibodies for detection of a gel-
loading control protein. 
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Autocrine IL-10-dependent activation of STAT3 is required for pathogenic 
MΦ differentiation 
 The next question was whether the IL-10/STAT3 pathway contributed to 
the generation of the pathogenic, pro-proliferative MΦ phenotype. Small molecule 
inhibitors of Stat3 were used to address this question. Using RAW MΦs, the 
concentration of Stat3 inhibitor VII 137(EMD Millipore, #573103) required to block 
Stat3 activation in response to ADPKD CM was determined (Figure 4.2 (A)). 
Using this concentration (3 µM), MΦs were then incubated in the presence or 
absence of Stat3 inhibitor VII during programming with ADPKD CM and the 
effects on the production of pro-proliferative activity measured (Figure 4.2 (B)). 
Stat3 Inhibitor VII also blocked the production of Arg1, an M2 marker studied in 
Chapter 2 (data not shown). While there was no significant effect of this drug on 
the proliferative activity of CM from unprogrammed MΦs, the Stat3 inhibitor 
completely blocked the induction of pro-proliferative activity caused by ADPKD 
programming (Figure 4.2 (B)). A second Stat3 inhibitor, Stattic 138(Santa Cruz 
Biotechnology, CAS 19983-44-9), also blocked STAT3 activation induced by 
ADPKD CM in human THP-1 MΦs (Figure 4.2 (C)). Importantly, this inhibitor 
also blocked MΦ production of enhanced pro-proliferative activity, while not 
affecting the proliferative activity in CMs collected from unprogrammed MΦs 
(Figure 4.2 (D)). 
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Figure 4.2: Inhibitors of Stat3 activation attenuate proliferative effect of MΦs. 
(A) Concentration of STAT3 inhibitor VI required to block STAT3 activation in RAW 
MΦs during programming with ADPKD CM. RAW MΦs were incubated in either 
media (C) or ADPKD CM for 18h in the absence or presence of increasing 
concentrations of STAT3 inhibitor VII prior to cell lysis.  Total protein was subjected 
to immunoblot analyses using anti-phospho-STAT3 antibodies, as well as anti-
RhoGDI antibodies for detection of a gel-loading control protein. (B) Effects of 
STAT3 inhibitor VII on development of RAW MΦ pro-proliferative phenotype. MΦs 
were incubated in either media (None) or ADPKD CM for 18h in the absence or 
presence of STAT3 Inhibitor VII (3 uM).  Media was then removed, and after a PBS 
wash, cells were incubated for a further 24h in basal media, which was then 
collected and tested for proliferative effects on ADPKD cells. FBS (0.1%) was 
added to CMs prior to addition of ADPKD cells. After 72h, cells were collected and 
assayed for relative proliferation. (C) Concentration of Stattic required to block 
STAT3 activation in THP-1 MΦs during programming with ADPKD CM. THP-1 MΦs 
were incubated in either media (C) or ADPKD CM for 18h in the absence or 
presence of increasing concentrations of STAT3 inhibitor VII prior to cell lysis. Total 
protein was subjected to immunoblot analyses using the indicated antibodies. (D) 
Effects of Stattic on development of THP-1 MΦ pro-proliferative phenotype. MΦs 
were incubated in either media (None) or ADPKD CM for 18h in the absence or 
presence of Stattic.  Media was then removed, and after a PBS wash, cells were 
incubated for a further 24h in basal media, which was then collected and tested for 
proliferative effects on ADPKD cells. FBS (0.1%) was added to CMs prior to 
addition of ADPKD cells. After 72h, cells were collected and assayed for relative 
proliferation. (E) Stattic addition to THP-1 MΦ cultures after 1 h of programming 
blunts late activation of STAT3. THP-1 MΦs were incubated in either media (C) or 
ADPKD CM for 1h prior to addition (or not) of Stattic (100 uM) and were incubated 
further for 17 h. Cells were lysed and total protein was subject to immunoblot 
analyses using the indicated antibodies. (F)Stattic addition to THP-1 MΦ cultures 
after 1 h of programming blunts development of THP-1 MΦ pro-proliferative 
phenotype. 
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A small molecule inhibitor of Stat3 was also used to determine whether the early 
or late activation of Stat3 during programming was required for the pathogenic, 
pro-proliferative phenotype. Stattic was incubated with THP-1 MΦs starting at 1 h 
after the addition of ADPKD CM, so that the early activation of Stat3 would be 
unperturbed. The addition of Stattic at this time again blocked both the activation 
of Stat3 when measured at 18 h (Figure 4.2 (E)) and the induction of pro-
proliferative activity (Figure 4.2 (F)). These results suggest that only the late 
Stat3 activation (stimulated by IL-10) is required for the generation of the pro-
proliferative activity elaborated by MΦs in response to programming with ADPKD 
CM. 
 
Activated STAT3 is present in MΦs in human ADPKD kidneys. 
 To determine whether MΦ STAT3 activation occurs in human disease, 
sections of human ADPKD cystic kidneys were stained using antibodies specific 
for both MΦs and phosphorylated STAT3. To stain MΦs, an antibody specific for 
CD163, a marker of M2-like MΦs that we previously showed reacted with over 
90% of the MΦs present in these kidneys4. First, antibodies for CD163 and anti-
phospho-STAT3 were used for immunohistochemical staining of adjacent serial 
sections of ADPKD cystic kidneys. In most MΦ-rich areas, nuclear phospho-
STAT3 positive cells were detected, whereas few if any of these cells were 
detected in areas of interstitium without MΦs (Figure 4.3 (A and B)). Nuclear 
phospho-STAT3 staining could also be detected within scattered cyst epithelial 
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cells, which has been reported by others 136, 139. Next, immunofluorescence co-
staining for CD163 and phospho-STAT3 was performed. In these experiments, 
occasional CD163-positive cells also showed nuclear phospho-STAT3 staining 
(Figure 4.3 (D)). These results indicate that STAT3 activation is present in a 
subset of renal MΦs present in cystic kidneys in vivo. 
 
NFκB Activation and Pathogenic Macrophage Programming 
 The data highlighted in Chapter 3 and thus far in this Chapter indicate that 
ADPKD cells secrete factor(s) responsible for pathogenic macrophage 
polarization. To identify the factors and their immediate signaling pathways, 
several approaches were taken. First, transcriptome data were analyzed. 
RNAseq expression data were obtained from THP-1 macrophages treated with 
ADPKD CM or control media (Sally Salah, unpublished observations). Forty-two 
genes were upregulated (ranging from 1.6 fold to 2951-fold) with p values <0.05 
in programmed versus unprogrammed macrophages (Table 1). Due to variability 
in the biological replicates, no transcripts had significant q values (p values 
adjusted for false discovery rate). However, several genes from this small set 
were validated with antibody detection (Sally Salah, unpublished observations). 
Thus, the entire set of 42 genes was used to query a public database designed to 
find common upstream regulators of gene sets. This analysis, ChIP Enrichment 
Analysis (ChEA) 140, examines publicly available data to identify common factors 
that have been associated by chromatin immunoprecipiation (ChIP) with the gene 
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sets entered. This tool has been used successfully to help identify factors 
relevant in kidney fibrosis 141. 
 ChEA analysis revealed a striking result. The top hit for the 42 genes 
upregulated in programmed macrophages was RelA, with a p value of 0. RelA, 
also known as p65, is a component of the prototypical NFκB heterodimer 
(p65/p50), a transcription factor complex that regulates both innate and adaptive 
immunity 142. To assess the potential involvement of NFκB in ADPKD-stimulated 
macrophage polarization, western blot analysis of IκB stability was performed. In 
macrophages treated with ADPKD CM, there was a rapid disappearance of IκB 
(Figure 4.4), indicating robust activation of the NFκB pathway. Activation was 
more pronounced than was observed for LPS, which is known to activate the 
pathway. To determine whether this activation was relevant to function of 
ADPKD-polarized macrophages, a small molecule NFκB inhibitor (JSH-23; 
Sigma-Aldrich, #J4455) was used. Macrophages were treated with ADPKD CM in 
the presence or absence of JSH-23. After programming and washout, 
macrophage CM was assessed for proliferative effects on ADPKD cells. As 
illustrated in Figure 4.4, NFκB inhibition resulted in a small but statistically 
significant diminution in the pro-proliferative phenotype. These data indicate that 
NFκB is activated in macrophages during programming by ADPKD cells and may 
be important for the generation of the pathogenic, pro-proliferative phenotype. 
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Figure 4.3: Phosphorylated STAT3 is present in macrophages of cystic ADPKD 
kidneys. Formalin-fixed, paraffin-embedded tissues from ADPKD kidneys were 
serially sectioned (A-C) and consecutive sections stained by immunohistochemistry 
using the M2 macrophage antibody, CD163 (A), the anti-phospho-STAT3 antibody 
(B) or buffer only (C) as a control for non-specific staining of the secondary antibody. 
Arrows indicate phospho-STAT3-positive cells in MΦ-rich regions of interstitium. (D 
and E) Section of similarly fixed and prepared sections of ADPKD kidneys co-stained 
with anti-CD163 (green), anti-phospho-STAT3 (red) antibodies followed by incubation 
with 2 distinct fluorescently-labeled secondary antibodies, each with the appropriate 
antibody specificity (shown in D), and with DAPI (shown in E) (. Arrowheads 
indicate co-staining cells, which were present in the interstitium. 
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Figure 4.4: ADPKD CM treatment activates NFκB in MΦ and plays a 
partial role in induction of the pro-proliferative phenotype. (A) THP-1 
macrophages were treated for the indicated times with either XIVVO or 
ADPKD CM. After the last treatment the cells were collected and processed 
for immunoblot analysis. The disappearance of IκB was observed over time, 
indicating the activation of NFκB in correlation. (B) THP-1 cells were 
programmed with XVIVO or ADPKD CM in the presence of the NFκB inhibitor 
JSH-23 for 18 hours, which was then washed out with PBS and DMEM. The 
MΦ CM was then collected and placed onto PKD cells for 72 hours. The 
treated PKD cells were collected and assayed for proliferation. JSH-23 had no 
effect on XVIVO-exposed cells (data not shown). 
A 
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Other Potential Contributing Signaling Pathways in Programmed 
Macrophages 
 The observation that an NFκB inhibitor partially blocked the programming 
effect of ADPKD CM on macrophages implies that the pathway is important for 
the differentiation. However, since the effect is partial, it is certainly possible that 
other signals, ligands, and pathways may also contribute. The investigation of 
other potential contributing pathways is underway. One potential pathway is that 
controlled by purinergic signaling. Signals from ATP and adenosine have been 
shown to influence macrophage polarization and function 143, and extracellular 
ATP has been shown to promote cyst cell proliferation 144, 145. Also, ATP is found 
in high levels in PKD cyst fluid 146, and cyst epithelial cells are known to secrete 
ATP 2-5X greater than non-cystic epithelial cells 146, 147. 
 To assess the function of extracellular ATP in pathogenic macrophage 
polarization, macrophages were incubated with increasing concentrations of 
ATP. Then, after washout, the macrophage CM was assessed for pro-
proliferative activity on PKD cells. Neither 0.1 or 5 mM ATP had influenced the 
proliferation (Figure 4.5, blue bars). In parallel, macrophages were incubated 
with ADPKD CM plus ATP, and macrophage CM was collected as described 
above after a washout. In this experiment, incubation with ADPKD CM enhanced 
the pro-proliferative activity. However, ATP inhibited this enhancement. 
Collectively, these results suggest that extracellular ATP is not likely to be 
involved in programming pathogenic macrophages in PKD. 
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Figure 4.5: ATP inhibits the proliferative effect of MΦ on PKD 
epithelial cells. THP-1 cells were treated with ADPKD CM in the 
presence of 100 μM or 5 mM ATP for 72 hours. Treated PKD cells were 
then collected and assayed for proliferation. 
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4. Discussion 
 In earlier chapters, data were presented that support the hypothesis that 
macrophages and cyst epithelial cells communicate with one another in a 
reciprocal fashion. These interactions have functional consequences, namely, the 
cyst cell-promoted polarization of the macrophages enhanced their secretion of 
pro-proliferative factors. Autocrine IL-10 was shown to be essential for this 
process. In this chapter, signaling pathways both upstream and downstream of 
IL-10 were examined. Elucidation of these pathways could more clearly define 
specific components that could be targeted for therapy in PKD. 
 Not surprisingly, Stat3 was shown to be activated in the ADPKD-
programmed macrophages as a result of IL-10 secretion. Data were also 
presented to support the hypothesis that Stat3 activation is critical for pathogenic 
macrophage polarization, enhancing their ability to produce pro-proliferative 
factors. Stat3 activation has been examined in PKD 136. This group found 
sustained Stat3 activation in cystic epithelial cells of both human ADPKD and 
mouse models of disease. An inhibitor of Stat3 (pyrimethamine) slowed disease 
progression in a mouse model; the therapeutic benefit was attributed to its effects 
on cyst cells. Notably, interstitial cells with activated Stat3 were present in this 
study but not characterized. It is possible that some of the benefits of this drug 
may be the result of effects on these interstitial cells, which are quite possibly 
macrophages. 
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 When considering the ADPKD cell-stimulated macrophage polarization 
process, responsible ligand(s) have not yet been identified. The polarizing activity 
is not sensitive to heat (not shown), so the ligand(s) are likely to be non-proteins 
(or perhaps small, heat-stable peptide). In this chapter, our data suggest that one 
candidate non-peptide ligand, ATP, which is highly secreted by ADPKD cells, is 
not the likely signal. Transcriptome analysis was used to identify relevant 
pathways activated during polarization and perhaps deduce upstream signaling 
events. This analysis suggested that NFκB activation is important for 
polarization. Examination of macrophage cell lysates demonstrated that NFκB is 
indeed robustly activated upon polarization by ADPKD CM. Potentially relevant to 
this observation is the proposed existence of a subtype of macrophage called 
M2d 148. This subtype plays a specific crucial role in tissue formation and 
expresses high levels of IL-10 and VEGF but lacks the expression of other typical 
M2 markers such as Ym1, Mrc1, and Retnla. Interestingly, putative M2d 
macrophages arise independent IL-4 or IL-13 but rather require NFκB signaling. 
This phenotypic description sounds very similar to what this dissertation has 
described in PKD. 
 NFκB signaling can be initiated by numerous signals. In macrophages, 
pattern recognition receptors, especially toll-like receptors (TLRs), are most 
important for NFκB activation 149. Future directions for this study will focus on 
TLRs as possible mediators of IL-10 production and subsequent pathogenic 
macrophage polarization. 
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Chapter Five 
Summary, Conclusions, and Future Directions 
 
 Polycystic kidney disease (PKD) represents a family of genetic disorders 
characterized by renal cystic growth and progression to kidney failure. No FDA 
approved treatment is currently available for individuals with PKD. With the 
discovery of the genes PKD1 and PKD2, mutations in which are the root cause of 
PKD, most research has focused on the subsequent cellular abnormalities that 
occur as a result of these mutations. Recently, however, there has been interest 
in studying non-cell autonomous factors that may affect disease progression. The 
research presented here focused on one such factor the involvement of the 
innate immune system.  
 A role for macrophages was first suggested when the observation was 
made that they were capable of promoting ADPKD cyst cell proliferation in vitro. 
The importance of macrophages in PKD was further supported by the discovery 
in our lab, as well as others, that chemical depletion of macrophages in vivo 
attenuated cyst growth and expansion in a murine model of ARPKD, the cpk 
mouse. With these observations, the environment of PKD kidneys bears a 
striking similarity to that of kidneys post-injury. In all cases of acute kidney injury, 
the presence of macrophages is initially detrimental to tissue regeneration, but 
once repair is the goal, macrophages play an important role in encouraging 
epithelial cell growth and healing. Importantly, though the role of macrophages 
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seems to be similar in AKI and PKD kidneys, it is important to note that in the 
case of PKD, the initial insult is never removed, leading to chronic injury. Thus, 
this work focused on characterizing the phenotype or polarization state of 
macrophages in PKD and determining the extent to which this state could 
contribute to disease state. 
 In this document, I presented data that supports the hypothesis that 
macrophages, once recruited, can be influenced by cystic PKD epithelia to 
differentiate to a harmful, pathogenic phenotype that promotes cyst expansion 
and disease progression. The hypothesis that follows this is that disease 
progression may be reduced if the signaling that leads to this macrophage 
polarization state or the subsequent proliferative influence on cystic epithelia 
could be interrupted. I further showed that IL-10 and its signaling pathway are 
critical for this process (Figure 5.1). Thus, the studies presented here suggest 
that Stat3 inhibitors, IL-10 neutralizing antibodies, or NFκB inhibitors could prove 
to be viable therapeutic interventions in PKD. Indeed, as mentioned above, 
pyrimethamine, which inhibits Stat3, has already been shown to be effective in 
animal models of PKD 136. Another critical characteristic of a potential PKD 
therapy is that it must be safe over long periods of time. Notably, with the Stat3 
inhibitor, this appears to be the case.  
  




Figure 5.1: Proposed Model by which IL-10 regulates a pathogenic macrophage 
phenotype in response to ADPKD stimulation. ADPKD cells secrete soluble, heat-
stabile factor(s), which induces macrophage IL-10 production in an NFκB-regulated 
fashion. IL-10 secreted from the macrophages signal in an autocrine fashion through 
Stat3 to induce a pathogenic macrophage phenotype. The ADPKD-polarized 
macrophages secrete one or more factors that promote accelerated proliferation of 
ADPKD cyst cells. The secreted factors from both the ADPKD cells and the 
macrophages are not yet known, but are currently being elucidated. However, this 
model indicates that there are three avenues by which to target the pathogenic 
macrophage conversion; inhibition or reduction of IL-10 signaling by direct targeting, 
upstream regulation via NFκB, and lastly regulation of Stat3 activation, directly 
downstream of IL-10. 
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 Though we have begun to study the effects of a global knockout of IL-10, it 
may prove more informative to study macrophage-specific IL-10 depletion, as 
global knockouts have other problems, especially in the gut. These animals 
develop inflammatory bowel disease. It is possible this could influence kidney 
disease 118, 119. The fact that we are presently unable to generate a double 
knockout (cpk-/-;Il10-/-) indicates that there may be a deleterious or fatal issue 
that arises in the case of total IL-10 loss in this particular mouse model. Small 
differences were detected in total kidney size in the heterozygotes compared to 
wild type, but we were unable to detect differences in total cystic index. The 
longevity or life expectancy of affected individuals may be different, so that would 
be important to study. 
 There are no specific treatments for PKD, but in the coming years, it may 
be most useful to consider combinatorial therapy rather than searching for one 
target. A two- or three-pronged attack may be the best approach, where a 
diseased individual would be treated with a cocktail of drugs: one that targets cell 
autonomous cyst growth, and another that targets the immune. Given the 
extensive time and investments that must be made to develop new drugs, it 
makes sense to look to drugs that are already in the stages of clinical trials. With 
this in mind, many of the targets examined in this study were chosen based on 
the knowledge of available drugs on the market. The hope is that the work 
presented here will contribute to the understanding of this complicated disease 
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and assist in the discovery of a viable, life-long treatment for those affected with 
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